composition of feed additive and its method of preparation, feed and its method of preparation, and

专利摘要:
FEED ADDITIVE COMPOSITION, DIRECT FEED MICRO-ORGANISM IN COMBINATION WITH A PROTEASE, A XYLANASE, A AMYLASE AND A PHYTASE, KIT, METHOD FOR PREPARING A FEED ADDITIVE COMPOSITION, FEED, METHOD OF PREPARATION OF THE REFERRED FOOD AND PREPARATION. The present invention relates to a feed additive composition that comprises a direct feed microorganism in combination with a protease, xylanase, amylase and phytase, and a method of improving an individual's performance or improving digestibility of a raw material in a feed (for example, digestibility of nutrients, such as amino acid digestibility), or to improve nitrogen retention, or to avoid the negative effects of necrotic enteritis or to improve the feed conversion ratio (FCR) or to improve weight gain in an individual or to improve food efficiency in an individual or to modulate (for example, improve) the individual's immune response or to promote the growth of beneficial bacteria in an individual's gastrointestinal tract, where the method comprises administering to a subject a direct-fed microorganism in combination with a protease, xylanase, amylase and phytase.
公开号:BR112013020684B1
申请号:R112013020684-5
申请日:2012-01-19
公开日:2020-11-10
发明作者:Luis Fernando Romero Millán
申请人:Dupont Nutrition Biosciences Aps；
IPC主号:

专利说明:

FIELD OF THE INVENTION
[0001] The present invention relates to methods of improving feed compositions using a direct feed microorganism in combination with a specific combination of enzymes, and to a feed additive composition comprising a direct feed microorganism in combination with a specific combination of enzymes. The present invention additionally relates to uses and kits. BACKGROUND OF THE INVENTION
[0002] Supplemental enzymes are used as additives for animal feed, particularly poultry and pig feed, as a means of improving nutrient utilization and production performance characteristics. Enzyme mixtures are available to enhance the nutritional value of diets containing soybean meal, animal protein meal or high-fiber food by-products.
[0003] The concept of direct-feed microorganisms (DFM) involves feeding beneficial microbes to animals, such as dairy cattle, when they are under periods of stress (disease, changes in feed, environmental or production challenges). Probiotics is another term for this category of feed additives. Probiotics or DFM have been shown to improve animal performance in controlled studies. DFMs include products based on bacteria or yeast directly fed.
[0004] Although combinations of DFMs with some enzymes have been contemplated, the interaction between DFMs and enzymes has never been fully understood. The present invention relates to innovative specific combinations that surprisingly significantly improve the performance characteristics of animal production. SUMMARY OF THE INVENTION
[0005] A seminal finding of the present invention is that a DFM in combination with a protease, xylanase, amylase and phytase has significant beneficial effects on an animal's performance.
[0006] In particular, a seminal finding of the present invention is that a DFM in combination with a protease, xylanase, amylase and phytase has significant beneficial effects on the performance of an animal, including improving one or more of the following: feed conversion (FCR), ability to digest a raw material (for example, digestibility of nutrients, such as amino acid digestibility), nitrogen retention, survival rate, carcass yield, growth rate, weight gain, feed efficiency, animals' resistance to necrotic enteritis, the individual's immune response, or the growth of beneficial bacteria in an individual's gastrointestinal tract.
[0007] Another surprising effect of the present invention is that it can reduce the excretion of nutrients in the manure content (e.g., reduce nitrogen and phosphorus) of an individual's manure.
[0008] In one aspect, the present invention provides a feed additive composition that comprises (or consists essentially of or consists of) a direct feed microorganism in combination with a protease, xylanase, amylase and phytase.
[0009] In another aspect, the present invention provides a method for improving an individual's performance or for improving the digestibility of a raw material in a feed (for example, nutrient digestibility, such as amino acid digestibility), or to improve nitrogen retention, or to avoid the negative effects of necrotic enteritis or to improve the feed conversion ratio (FCR) or to improve weight gain in an individual or to improve food efficiency in an individual or to modulate ( for example, improving) an individual's immune response, or to promote the growth of beneficial bacteria in an individual's gastrointestinal tract, or to reduce populations of pathogenic bacteria in an individual's gastrointestinal tract, or to reduce the excretion of nutrients in manure, the method comprising administering to a subject a direct-fed microorganism in combination with a protease, a xylanase, an amylase and a strip if.
[00010] An additional aspect of the present invention is the use of a direct-fed microorganism in combination with a protease, xylanase, amylase and phytase to improve an individual's performance or to improve the digestibility of a raw material in a ration (for example, digestibility of nutrients, such as amino acid digestibility), or to improve nitrogen retention, or to avoid the negative effects of necrotic enteritis or to improve feed conversion ratio (FCR) or to improve weight gain weight in an individual or to improve food efficiency in an individual or to modulate (for example, improve) the individual's immune response, or to promote the growth of beneficial bacteria in an individual's gastrointestinal tract, or to reduce populations of pathogenic bacteria in an individual's gastrointestinal tract, or to reduce the excretion of nutrients in manure.
[00011] In another aspect of the present invention, a kit is provided which comprises a direct-fed microorganism, a protease, a xylanase, an amylase, a phytase (and, optionally, at least one vitamin and / or optionally, at least mineral) and instructions for administration.
[00012] In another aspect, the present invention provides a method for preparing a feed additive composition, which comprises mixing a direct feed microorganism with a protease, xylanase, amylase and phytase and (optionally) packaging.
[00013] In a still further aspect, the present invention provides a feed or animal feed that comprises (or consists essentially of or consists of) a direct feed microorganism in combination with a protease, xylanase, amylase and phytase.
[00014] A premix comprises a feed additive composition that comprises (or consists essentially of or consists of) a feed microorganism in combination with a protease, xylanase, amylase and phytase, and at least one mineral and / or at least one vitamin.
[00015] In another aspect, the present invention provides a method for preparing an animal feed that comprises mixing a feed component with a feed additive composition that comprises (or consists essentially of or consists of) a direct feed microorganism in combination with a protease, xylanase, amylase and phytase.
[00016] In another aspect, the present invention relates to a feed additive composition for the prevention and / or treatment of coccidiosis and / or necrotic enteritis in an individual.
[00017] The present invention further provides a method for preventing and / or treating necrotic enteritis and / or coccidiosis wherein an effective amount of a feed additive composition according to the present invention is administered to an individual. BRIEF DESCRIPTION OF THE DRAWINGS
[00018] Figure 1 shows that a combination of DFM (Enviva Pro® available from Danisco A / S) with a combination of a xylanase (for example, a Trichoderma xylanase endo-xylanase), an amylase (for example, a Bacillus licheniformis alpha-amylase), a protease (for example, Bacillus subtilis protease) and a phytase (for example, 500 FTU / kg Phyzyme XP (an E. coli phytase) available from Danisco A / S) significantly improved (reduced) the classification of necrotic enteritis lesions in the animals' gastrointestinal tract compared to the stimulated control. In some embodiments, xylanase, amylase and protease can be formulated together in AxtraXAP® [containing 2,000 Xll / kg of xylanase feed; 200 All / kg of amylase feed and 4,000 Pll / kg of protease feed] also available from Danisco A / S).
[00019] Figure 2 shows that a combination of (Enviva Pro® available from Danisco A / S) with a combination of a xylanase (for example, a Trichoderma xylanase endo-xylanase), an amylase (for example, a Bacillus licheniformis alpha-amylase), a protease (eg Bacillus subtilis protease) and phytase (eg 500 FTU / kg Phyzyme XP (an E. coli phytase) available from Danisco A / S) improved significantly increased body weight gain (BW gain) in broilers stimulated with Clostridium perfringens compared to the stimulated control - even if resulting in an improved BW gain over a negative control (ie, an unstimulated control). This was significantly better than any other combination of enzymes, such as amylase and phytase or protease and phytase, and significantly better than the DFM applied to the stimulated control. In some embodiments, xylanase, amylase and protease can be formulated together in AxtraXAP® [containing 2,000 XU / kg of xylanase feed; 200 AU / kg of amylase feed and 4,000 PU / kg of protease feed] also available from Danisco A / S). Standard deviation of the mean (SEM) grouped = 28.6
[00020] Figure 3 shows that a combination of (Enviva Pro® available from Danisco A / S) with a combination of a xylanase (for example, a Trichoderma xylanase endo-xylanase), an amylase (for example, a Bacillus licheniformis alpha-amylase), a protease (eg Bacillus protease subtilis) and phytase (eg 500 FTU / kg Phyzyme XP (an E. coll phytase) available from Danisco A / S) significantly improved the feed conversion ratio (FCR) (g of feed intake / g of PC gain) in broilers stimulated with Clostridium perfringens up to the level of unstimulated birds. This was significantly better than other combinations of enzymes with DFM such as amylase and phytase or protease and phytase. In some embodiments, xylanase, amylase and protease can be formulated together in AxtraXAP® [containing 2,000 Xll / kg of xylanase feed; 200 AU / kg of amylase ration and 4,000 Pll / kg of protease ration] also available from Danisco A / S).
[00021] Figure 4 shows the expression of relative IFN-g mRNA used as a marker of inflammation in the intestine, and shows that a combination of DFM (Enviva Pro®) with a combination of xylanase, amylase, protease and phytase (Avizyme 1502 ® available from Danisco A / S + 500 FTU / kg Phyzyme XP (an E. coll phytase) increased IFN-g expression in 11 days and reduced this expression in 20 days.
[00022] Figure 5 shows the digestible energy of the apparent ileum (mCal / kg) and shows that a combination of DFM (Enviva Pro®) with a xylanase, amylase, protease and phytase (two different enzyme mixtures were used, the first was Avizyme 1502® available from Danisco A / S + 500 FTU / kg Phyzyme XP (an E. coll phytase) ', and the second was AxtraXAP [containing 2,000 XU / kg of xylanase feed; 200 AU / kg of amylase ration and 4,000 PU / kg protease ration] also available from Danisco A / S + 500 FTU / kg Phyzyme XP (an E. coli phytase) significantly improved the effects of energy digestibility.
[00023] Figure 6 shows that the digestibility of amino acids has improved significantly with a combination of DFM (Enviva Pro®) with a xylanase, amylase, protease and phytase. Improving the digestibility of undigested amino acid fractions at the ileum level with a combination of DMF with xylanase, amylase, protease and phytase was more than improving DFM alone or the combination of xylanase, amylase, protease and phytase without DFM.
[00024] Figure 7 shows enhanced energy digestibility with a combination of DFM (Enviva Pro®) with xylanase, amylase, protease and phytase.
[00025] Figure 8 shows the apparent metabolizable energy corrected for the AMEn nitrogen from dietary treatments given to broilers with 17 to 21 days of age.
[00026] Figure 9 shows that a combination of DFM (Enviva Pro®) with a xylanase, amylase, protease and phytase (two different enzyme mixtures were used, the first was Avizyme 1502® available from Danisco A / S + 500 FTU / kg Phyzyme XP (an E. coli phytase) ', and the second was AxtraXAP also available from Danisco A / S + 500 FTU / kg Phyzyme XP (an E. coli phytase) significantly improved nitrogen retention .
[00027] Figure 10 shows that a combination of DFM (Enviva Pro®) with xylanase, amylase, protease and phytase (Avizyme 1502® available from Danisco A / S + Phyzyme XP (an E. coli phytase)) reduces significantly the abundance of MUC-2 mRNA in the scrapes of ileum mucosa on day 14 treated with a high-dose coccidine vaccine, in hatch, compared to stimulated and unstimulated control treatments.
[00028] Figure 11 shows the amino acid sequence (SEQ ID NO. 1) of a pepsin resistant alpha amylase from Bacillus licheniformis.
[00029] Figure 12 shows the nucleotide sequence (SEQ ID NO. 2) of a pepsin resistant alpha amylase from Bacillus licheniformis.
[00030] Figure 13 shows the amino acid sequence (SEQ ID NO. 3) of a Pepsin-resistant alpha amylase from Trichoderma reissue.
[00031] Figure 14 shows the nucleotide sequence (SEQ ID NO. 4) of a Pepsin resistant alpha amylase from Trichoderma reissue.
[00032] Figure 15 shows the feed conversion ratio for broilers at day 48 of age.
[00033] Figure 16 shows a heat map of the expression profiles of the genes of interest for all treatments for fasting at 23 days of age. Control not stimulated = Control not stimulated + phytase CC = Control stimulated + phytase CC + Amylase = Control stimulated + phytase + amylase CC + XAP = Control stimulated + phytase + xylanase + amylase + protease CC + EP = Control stimulated + phytase + Enviva Pro CC + EP + Amylase = Control stimulated + phytase + amylase + Enviva Pro CC + EP + XAP = Control stimulated + phytase + xylanase + amylase + protease + Enviva Pro.
[00034] Figure 17 shows a heat map of the chicken alpha amylase expression profile for all treatments in the pancreas at 23 days of age. Control not stimulated = Control not stimulated + phytase CC = Control stimulated + phytase CC + Amylase = Control stimulated + phytase + amylase CC + XAP = Control stimulated + phytase + xylanase + amylase + protease CC + EP = Control stimulated + phytase + Enviva Pro CC + EP + Amylase = Control stimulated + phytase + amylase + Enviva Pro CC + EP + XAP = Control stimulated + phytase + xylanase + amylase + protease + Enviva Pro.
[00035] Figure 18 shows the apparent metabolizable energy corrected by the nitrogen retention (AMEn) of broilers with 21 days of age. DFM effect; P <0.001; Enzyme effect; P <0.001; DFM x Enzyme effect; P = 0.27; Standard deviation of the grouped mean (SEM) = 32 kcal.
[00036] Figure 19 shows the feed conversion ratio (FCR) of broilers in a necrotic enteritis stimulus model (grouped SEM: 0.015).
[00037] Figure 20 shows the relative proportion of Lactobacillus spp. in 21 days in the jejunum in broilers, ChSq <0.0001. DETAILED DESCRIPTION OF THE INVENTION
[00038] Preferably, the enzyme (s) used in the present invention is / are exogenous to DFM. In other words, the enzyme (s) is / are preferably added or mixed with the DFM.
[00039] Except where otherwise stated, all technical and scientific terms used in the present invention have the same meaning as understood by the person skilled in the art to which this description belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York, USA (1994), and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY, USA (1991 ) provide a technical background with a general dictionary of many terms used in the description.
[00040] This description is not limited to the exemplary methods and materials presented here, and any methods and materials similar or equivalent to those described here can be used in practice or testing the modalities of this description. Numeric ranges include the numbers that define the range. Unless otherwise noted, any nucleic acid sequences are written from left to right in the 5 'to 3' orientation; the amino acid sequences are written from left to right in the amino orientation for carboxy, respectively.
[00041] The titles provided here are not limitations on the various aspects or modalities of this description, which can be admitted by reference to the specification as a whole. Consequently, the terms defined immediately below are more fully defined by reference to the specification as a whole.
[00042] Amino acids are designated here using the name of the amino acid, the three letter abbreviation or the one letter abbreviation.
[00043] The term "protein", for use in the present invention, includes proteins, polypeptides, and peptides.
[00044] For use in the present invention, the term "amino acid sequence" is synonymous with "polypeptide" and / or the term "protein". In some cases, the term "amino acid sequence" is synonymous with the term "peptide"; in some cases, the term "amino acid sequence" is synonymous with the term "enzyme".
[00045] The terms "protein" and "polypeptide" are used interchangeably in the present invention. In the present description and in the vindications, conventional one-letter and three-letter codes for amino acid residues can be used. The 3-letter code for amino acids, as defined in accordance with the Commission, is the Joint Biochemical Nomenclature (JCBN) of IUPACIUB. It should also be understood that a polypeptide can be encoded by more than one nucleotide sequence due to the degeneration of the genetic code.
[00046] Other definitions of terms may appear throughout the specification. Before the exemplifying modalities are described in detail, it should be understood that this description is not limited to the particular modalities described, since this can, of course, vary. It should also be understood that the terminology used in the present invention is only for the purpose of describing the particular modalities, and is not intended to be limiting, since the scope of the present description will be limited only by the appended claims.
[00047] When a range of values is provided, it is understood that each intervening value, up to the tenth of the lower limit unit unless the context clearly determines otherwise, between the upper and lower limits of that range was also specifically presented . Each minor range between any declared value or intervening value in a declared range and any other established or intervening value in which the established range is covered within this description. The upper and lower limits of these minor ranges can be independently included or excluded in the range and each range where either, none, or both limits are included in the lower ranges is also included in this description, subject to any limit excluded specifically from the established range. When the established range includes one or both of the limits, bands that exclude one or both of these included limits are also included in this description.
[00048] It should be noted that, as used here and in the appended claims, the singular forms "o", "a", "um", "an" include references in the plural unless the context clearly determines otherwise . Thus, for example, reference to "an enzyme" includes a plurality of these candidate agents, and reference to "the feed" includes reference to one or more feeds and their equivalents known to those skilled in the art, and so on.
[00049] The publications discussed here are provided for description only prior to the filing date of this application. Nothing in them should be considered an admission that such publications constitute prior art to the appended claims.
[00050] Enzymes for use in the present invention can be produced by solid or submerged culture, including batch, fed batch and continuous flow processes. The culture is made in a growth medium that comprises an aqueous medium with mineral salts, organic growth factors, the material source of carbon and energy, molecular oxygen, and, of course, an initial inoculum of one or more species of specific microorganisms that will be employed. Direct feed microorganism (DFM)
[00051] The term "microbial" of the present invention is used interchangeably with "microorganism".
[00052] Preferably, the DFM comprises a viable microorganism. Preferably, DFM comprises viable bacteria or viable yeast or viable fungi.
[00053] In a preferred embodiment, DFM comprises a viable bacterium.
[00054] The term "viable microorganism" means a microorganism that is metabolically active or capable of differentiating.
[00055] In one embodiment, DFM can be a spore-forming bacterium and, therefore, the term DFM can be comprised of or can contain spores, for example, bacterial spores. Therefore, in one embodiment, the term "viable microorganism" for use in the present invention can include microbial spores, such as endospores or conidia.
[00056] In another embodiment, DFM in the feed additive composition according to the present invention is not comprised of or does not contain microbial spores, for example, endospores or conidia.
[00057] The microorganism can be a naturally occurring microorganism or it can be a transformed microorganism. The microorganism can also be a combination of suitable microorganisms.
[00058] In some respects, the DFM according to the present invention can be one or more of the following: a bacterium, a yeast, a fungus.
[00059] Preferably, the DFM according to the present invention is a probiotic microorganism.
[00060] In the present invention, the term direct feed microorganism (DFM) encompasses direct feed bacteria, direct feed yeasts, direct feed fungi and combinations thereof.
[00061] Preferably, DFM is a direct-feeding bacterium.
[00062] Preferably, DFM is a combination comprising two or more bacteria, for example, three or more or four or more; or DFM is a combination that comprises two or more bacterial strains, for example, three or more or four or more.
[00063] Preferably, the bacterium or bacteria is or are isolated (s).
[00064] Suitably, the DFM can comprise a bacterium of one or more of the following genera: Lactobacillus, Lactococcus, Streptococcus, Bacillus, Pediococcus, Enterococcus, Leuconostoc, Carbacterium, Propionibacterium, Bifidobacterium, Clostridium and Combinations of the same and different types of gas and gas. .
[00065] In one modality, DFM can be selected from the following Bacillus spp: Bacillus subtilis, Bacillus cereus, Bacillus licheniformis and Bacillus amyloliquefaciens.
[00066] In one embodiment, DFM can be a combination that comprises two or more strains of Bacillus.
[00067] In one embodiment, DFM can be a combination of two or more of the strains of Bacillus subtilis 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B-50634).
[00068] Strains 3A-P4 (PTA-6506), 15A-P4 (PTA-6507) and 22C-P1 (PTA-6508) are available to the public from the American Type Culture Collection (ATCC).
[00069] The 2084 strains (NRRL B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105) are available to the public from the Agricultural Research Service Culture Collection (NRRL). The strain of Bacillus subtilis LSSA01 is sometimes called B. subtilis 8.
[00070] These strains are taught in US 7,754,469 B2.
[00071] Bacillus subtilis BS 18 and Bacillus subtilis BS 278 were deposited by Andy Madisen of W227 N752 Westmound Dr. Waukesha, Wl 53186, USA or Danisco USA Inc. of W227 N752 Westmound Dr. Waukesha, Wl 53186, USA of according to the Budapest Treaty at the Agricultural Research Service Culture Collection (NRRL) at 1815 North University Street, Peoria, Illinois 61604, United States of America, under the deposit numbers NRRL B-50633 and NRRL B-50634, respectively, on January 9, 2012.
[00072] Andy Madisen of W227 N752 Westmound Dr. Waukesha, Wl 53186, USA and Danisco USA Inc. of W227 N752 Westmound Dr. Waukesha, Wl 53186, USA authorize Danisco A / S of Langebrogade 1, PO Box 17, DK- 1001, Copenhagen K, Denmark referring to these biological materials deposited in this patent application and gave unreserved and irrevocable consent to the deposited material being made available to the public.
[00073] In some modalities, DFM can be a combination comprising strains of Bacillus subtilis, as detailed in the table below:

[00074] In one embodiment, DFM can be selected from the following Lactococcus spp: Lactococcus cremoris and Lactococcus lactis and combinations thereof.
[00075] In one embodiment, DFM can be selected from Lactobacillus spp following: Lactobacillus buchneri, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus kefiri, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus cur- vatus, Lactobacillus bulgaricus, Lactobacillus sakei, Lactobacillus reuteri, Lactobacillus fermentum, Lactobacillus farciminis, Lactobacillus lactis, Lactobacillus delbreuckii, Lactobacillus plantarum, Lactobacillus paraplantarum, Lactobacillus farciminis, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus johnsonii Lactobacillus jensenii and combinations of any of them.
[00076] In one modality, DFM can be selected from the following Bifidobacteria spp: Bifidobacterium lactis, Bifidobacterium bifidium, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantil, Bifidobacterium infantil, Bifidobacterium catenulatum, bifidobatum, bifidobacterium, Bifidobacterium and combinations of any of them.
[00077] Suitably, the DFM may comprise a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus, Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidus , Lactococcus lactis, Bifidobacterium bifidum, Bacillus subtilis, Propionibacterium thoenii, Lactobacillus farciminis, Lactobacillus rhamnosus, Megasphaera elsdenii, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. Salivarius, Propionibacteria sp and combinations thereof.
[00078] The direct-feeding bacteria used in the present invention may be of the same type (genus, species and strain) or may comprise a mixture of genera, species and / or strains.
[00079] Suitably, the DFM according to the present invention can be one or more of the products or the microorganisms contained in these products, according to the table below:



[00080] In one modality, properly, the DFM can be Enviva Pro®. Enviva Pro® is commercially available from Danisco A / S and is a combination of the Bacillus 2084 strain, NRRI B-50013 accession, the Bacillus LSSAO1 strain, NRRL accession B- 50104 and the Bacillus strain 15A-P4 ATCC, accession number PTA-6507 (as shown in US 7,754,469 B - incorporated herein by way of reference).
[00081] Suitably, the DFM can comprise a yeast of the genus: Saccharomyces spp.
[00082] Preferably, the DFM that will be used in accordance with the present invention is a microorganism that is generally recognized as safe and that is preferably GRAS approved.
[00083] One skilled in the art will easily have knowledge of species and / or strains of microorganisms of the genera described here that are used in food and / or agricultural industries and that are generally considered suitable for animal consumption.
[00084] Preferably, the DFM used in accordance with the present invention is suitable for animal consumption.
[00085] Advantageously, when the product is a feed or feed additive composition, the viable DFM must remain effective until the normal "expiration" or "expiration" date of the product during which the feed or feed additive composition is offered for sale by the distributor. The desired time periods and normal shelf life will vary from feed to feed and those skilled in the art will recognize that lifetimes will vary depending on the type of feed, the size of the feed, storage temperatures, processing conditions , packaging material and packaging equipment.
[00086] In some modalities, it is important that DFM is heat tolerant, that is, it is thermotolerant. This is particularly the case in which the feed is pelleted. Therefore, in one embodiment, DFM can be a thermotolerant microorganism, such as a thermotolerant bacterium, including, for example, Bacillus spp.
[00087] In some embodiments, it may be preferable for DFM to be a pore-forming bacteria, such as Bacilli, for example, Bacillus spp. Bacilli are capable of forming stable endospores when the conditions for growth are unfavorable and are very resistant to heat, pH, humidity and disinfectants.
[00088] In one embodiment, DFM can appropriately reduce or prevent the intestinal establishment of pathogenic microorganisms (such as Clostridium perfringens and / or E. coli and / or Salmonella spp and / or Campylobacter spp.).
[00089] The DFM according to the present invention can be any suitable DFM. In one embodiment, the following "DFM assay" can be used to determine the suitability of a microorganism to be a DFM. For the sake of clarity, in one embodiment, a DFM selected as the inhibitory strain (or an antipathogen DFM) according to the "DFM assay" taught here is a DFM suitable for use according to the present invention, that is, in the feed additive composition according to the present invention. DFM Assay:
[00090] Each tube was seeded with a pathogen representative of a representative grouping.
[00091] The supernatant of a potential DFM grown aerobically or anaerobically was added to the seeded tubes and incubated.
[00092] After incubation, the optical density (OD) of the control tubes and with treated supernatant was measured for each pathogen.
[00093] Strain colonies (potential DFM) that produced reduced DO compared to the control were classified as an inhibitory strain (or an antipathogenic DFM).
[00094] The DFM assay, as used here, is explained in more detail in US2009 / 0280090 - incorporated here for reference.
[00095] Preferably, the representative pathogen used in the assay is one (or more) of the following: Clostridium, such as Clostridium perfringes and / or Clostridium difficile, and / or E. coli and / or Salmonella spp and / or Campylobacter spp . In a preferred embodiment, the assay is conducted with one or more of Clostridium perfringens and / or Clostridium difficile and / or E. coli, preferably Clostridium perfringens and / or Clos-tridium difficile, more preferably Clostridium perfringens.
[00096] In one embodiment, the DFM of the present invention is preferably an antipathogen.
[00097] The term "antipathogen", as used here, means that DFM is opposed to an effect (negative effect) of a pathogen.
[00098] In one embodiment, to determine whether a DFM is an antipathogenic DFM, the DFM assay mentioned above can be used. A DFM is considered an antipathogen or an antipathogenic DFM, if it is classified as an inhibitory strain in the aforementioned "DFM assay", for example, when the pathogen is Clostridium perfringens.
[00099] In one embodiment, the antipathogen DFM can be one or more of the following bacteria: Bacillus subtilis strain 2084 accession number NRRI B-50013, Bacillus subtilis strain LSSAO1, accession number NRRL B- 50104, strain of Bacillus subtilis 15A-P4 ATCC accession number PTA-6507, Bacillus subtilis strain 3A-P4, ATCC accession number PTA-6506, and Bacillus subtilis BS27 strain, ATCC accession number NRRL B-50105.
[000100] For the sake of clarity, these strains are available and are referred to in US 7,754,459 B.
[000101] In one embodiment, the DFM used in accordance with the present invention is not the strain of Lactobacillus gasseri BNR 17, accession number KCTC 10902BP, as presented in W02008 / 016214.
[000102] Preferably, DFM is not an inactivated microorganism.
[000103] In one embodiment, DFM, as used here, is a composition that comprises one or more DFM microorganisms, as described here. The composition may further comprise the enzymes of the present invention. The composition can be fed to an animal as a direct-feed microorganism (DFM). One or more vehicles or other ingredients can be added to DFM. DFM can be presented in various physical forms, for example, as a coating, as a water-soluble concentrate for use as a liquid syrup or to be added to a milk substitute, gelatin capsule, or gels. In a form of coverage, the freeze-dried fermentation product is added to a vehicle, such as whey, maltodextrin, sucrose, dextrose, limestone (calcium carbonate), rice husks, yeast culture, dry starch, and / or silica sodium aluminate. In a water-soluble concentrate modality for a liquid syrup or milk substitute supplement, freeze-dried fermentation product is added to a water-soluble vehicle, such as whey, maltodextrin, sucrose, dextrose, dry starch, silico aluminate sodium, and a liquid is added to form the syrup or the supplement is added to milk or a milk substitute. In a gelatin capsule form, the freeze-dried fermentation product is added to a vehicle, such as whey, maltodextrin, sugar, limestone (calcium carbonate), rice husks, yeast culture, dry starch and / or silica sodium aluminate. In one embodiment, the bacteria and vehicle are placed in a degradable gelatin capsule. In a gel form embodiment, the freeze-dried fermentation product is added to a vehicle, such as vegetable oil, sucrose, silicon dioxide, polysorbate 80, propylene glycol, butylated hydroxy anisol, citric acid, ethoxyquin, and / or colored artificial to form the gel.
[000104] DFM (s) can (optionally) be mixed with a dry formulation of additives including, but not limited to, growth substrates, enzymes, sugars, carbohydrates, extracts and micro-ingredients growth promoters. Sugars could include the following: lactose; maltose; dextrose; malto-dextrin; glucose; fructose; mannose; tagatose; sorbose; raffinose; and galactose. Sugars range from 50 to 95%, individually or in combination. The extracts could include soluble yeast fermentation or dry yeast in the 5 to 50% range. Growth substrates could include: tripticase, in the range of 5 to 25%; sodium lactate, in the range of 5 to 30%; and, Tween 80, in the range of 1 to 5%. Carbohydrates could include mannitol, sorbitol, adonitol and arabitol. Carbohydrates could be in the range of 5 to 50% individually or in combination. Micro-ingredients could include the following: calcium carbonate, in the 0.5 to 5.0% range; calcium chloride, in the range of 0.5 to 5.0%; di-potassium phosphate, in the range of 0.5 to 5.0%; calcium phosphate, in the range of 0.5 to 5.0%; manganese proteinate, in the range of 0.25 to 1.00%; and manganese, in the range of 0.25 to 1.0%.
[000105] To prepare the DFMs described here, the culture (s) and vehicle (s) (when used) can be added to a tape or paddle mixer and mixed for about 15 minutes, although the timing can be increased or reduced. The components are mixed in a way that results in a uniform mixture of cultures and vehicles. The final product is preferably a dry flowable powder. The DFM (s) or composition comprising the same can be added to an animal feed or a feed premix, added to an animal's water, or administered in other ways known in the art (preferably simultaneously with enzymes of the present invention). An animal feed can be supplemented with one or more DFM (s) described herein or with a composition described herein.
[000106] By "a mixture of at least two strains," is meant a mixture of two, three, four, five, six or even more strains. In some modalities of a mixture of strains, the proportions can vary from 1% to 99%. Other modalities of a mixture of strains are from 25% to 75%. Additional modalities of a mixture of strains are approximately 50% for each strain. When a mixture comprises more than two strains, the strains can be present in substantially equal proportions or in different proportions in the mixture.
[000107] DFM can be administered properly.
[000108] Suitably, DFM dosages in the feed can be between about 1x103 CFU / g of feed to about 1x109 CFU / g of feed, suitably, between about 1x104 CFU / g of feed at about 1x108 CFU / g of feed, appropriately, between about 7.5x104 CFU / g of feed to about 1x107 CFU / g of feed.
[000109] In one modality, DFM is administered in the feed more than about 1x103 UFC / g of feed, appropriately, more than about 1x104 UFC / g of feed, appropriately, more than about 7.5x104 UFC / g of feed.
[000110] Suitably, DFM dosages in the feed additive composition can be between about 1x105 CFU / g of composition to about 1x1013 CFU / g of composition, suitably, between about 1x106 CFU / g of composition at about 1x1012 UFC / g of composition, appropriately, between about 3.75x107 UFC / g of composition to about 1x1011 UFC / g of composition.
[000111] In one embodiment, DFM is administered in the feed additive composition to more than about 1x105 UFC / g of composition, appropriately, more than about 1x106 UFC / g of composition, appropriately, more than about 3, 75x107 UFC / g of composition.
[000112] In one embodiment, DFM is administered in the feed additive composition at more than about 2x105 CFU / g of composition, suitably, more than about 2x106 cfu / g of composition, appropriately, more than about 3.75x107 CFU / g of composition.
[000113] For use in the present invention, the term "UFC" means colony-forming units and is a measure of viable cells in which a colony represents an aggregate of cells derived from a single progenitor cell. Xylanase
[000114] Xylanase is the name given to a class of enzymes that degrade the linear polysaccharide beta-1,4-xylan in xylose, thus degrading hemicellulose, one of the main components of plant cell walls.
[000115] The xylanase for use in the present invention can be any commercially available xylanase.
[000116] Suitably, xylanase can be an endo-1,4-β-d-xylanase (classified as E.C. 3.2.1.8) or a 1.4 β-xylosidase (classified as E.C. 3.2.1.37).
[000117] In one embodiment, preferably, xylanase in an endoxylanase, for example, an endo-1,4-β-d-xylanase. The classification for an endo-1,4-β-d-xylanase is E.C. 3.2.1.8.
[000118] In one embodiment, the present invention relates to a DFM in combination with an endoxylanase, for example, an endo-1,4-β-d-xylanase, and another enzyme.
[000119] All E.C. enzyme classifications mentioned herein refer to the classifications provided in the document Enzyme No-menclature - Recommendations (1992) of the nomenclature committee of the International Union of Biochemistry and Molecular Biology - ISBN 0- 12-226164-3.
[000120] Suitably, the xylanase for use in the present invention can be a xylanase from Bacillus, Trichoderma, Thermomyces, Aspergillus and Penicillium.
[000121] In one embodiment, xylanase can be xylanase in Axtra XAP® or Avizyme 1502®, both products commercially available from Danisco A / S.
[000122] In a preferred embodiment, the xylanase for use in the present invention can be one or more of the xylanases in one or more of the commercial products below:




[000123] Preferably, xylanase is present in the feed in a range of about 500 XU / kg to about 16,000 XU / kg of feed, more preferably, about 750 XU / kg of feed to about 8,000 XU / kg of feed, and even more preferably about 1,000 XU / kg of feed to about 4,000 XU / kg of feed.
[000124] In one embodiment, xylanase is present in the feed at more than about 500 XU / kg of feed, suitably, more than about 600 XU / kg of feed, suitably, more than about 700 XU / kg of feed suitably more than about 800 XU / kg of feed, suitably more than about 900 XU / kg of feed, suitably more than about 1,000 XU / kg of feed.
[000125] In one embodiment, xylanase is present in the feed less than about 16,000 XU / kg of feed, suitably less than about 8,000 XU / kg of feed, suitably less than about 7,000 XU / kg of feed suitably less than about 6,000 XU / kg of feed, suitably less than about 5,000 XU / kg of feed, suitably less than about 4,000 XU / kg of feed.
[000126] Preferably, xylanase is present in the feed additive composition in a range of about 100 XU / g to about 320,000 XU / g of composition, more preferably, about 300 XU / g of composition at about 160,000 XU / g of composition, and most preferably about 500 XU / g of composition at about 50,000 XU / g of composition, and most preferably about 500 XU / g of composition at about 40,000 XU / g composition.
[000127] In one embodiment, xylanase is present in the feed additive composition at more than about 100 XU / g of composition, suitably, more than about 200 XU / g of composition, suitably, more than about 300 XU / g of composition, suitably, more than about 400 XU / g of composition, suitably, more than about 500 XU / g of composition.
[000128] In one embodiment, xylanase is present in the feed additive composition less than about 320,000 XU / g of composition, suitably less than about 160,000 XU / g of composition, suitably, less than about 50,000 XU / g of position, suitably less than about 40,000 XU / g of position, suitably less than about 30,000 XU / g of position.
[000129] It will be understood that a unit of xylanase (XU) is the amount of enzyme that releases 0.5 pmol of reducing sugar equivalents (such as xylose by the dinitrosalicylic acid test (DNS) - reducing sugar method) from a oat-wheat spelled xylan substrate per minute at pH 5.3 and 50 ° C. (Bailey, M.J. Biely, P. and Poutanen, K., Journal of Biotechnology, Volume 23, (3), May 1992, 257-270).
[000130] In one embodiment, the enzyme is appropriately classified using the above EC classification, and the EC classification designates an enzyme that has this activity when tested in the assay taught here to determine 1 XU. Amylase
[000131] Amylase is the name given to a class of enzymes capable of hydrolyzing starch in short-chain oligosaccharides such as maltose. The glucose portion can then be more easily transferred from maltose to a monoglyceride or glycosyl monoglyceride than from the original starch molecule.
[000132] The term amylase includes a-amylases (E.C. 3.2.1.1), G4-forming amylases (E.C. 3.2.1.60), β-amylases (E.C. 3.2.1.2) and y-amylases (E.C. 3.2.1.3).
[000133] In one embodiment, preferably, amylase is an amylase. Α-amylases are classified as (E.C. 3.2.1.1).
[000134] They may include amylases of bacterial or fungal origin, and chemically modified or chemically engineered mutants are included.
[000135] In one embodiment, preferably, the amylase can be an amylase, for example, a Bacillus licheniformis a-amylase and / or an amylase, for example, a Bacillus amylolique-faciens α-amylase.
[000136] In one embodiment, a-amylase can be a-amylase in Axtra XAP® or Avizyme 1502®, both products commercially available from Danisco A / S.
[000137] In another embodiment, the amylase can be a pepsin resistant a-amylase, such as a Trichoderma alpha amylase (like Trichoderma reesei) resistant to pepsin. An appropriately pepsin-resistant a-amylase is taught in UK application number 1011513.7 (which is incorporated by reference) and PCT / IB2011 / 053018 (which is incorporated by reference).
[000138] In one embodiment, the amylase can be a pepsin-resistant a-amylase that comprises or consists of an amino acid sequence: i) shown in SEQ ID NO. 1 or SEQ ID NO. 3; ii) presented in SEQ ID NO. 1 or SEQ ID NO. 3 except for one or more amino acid additions / insertions, deletions or substitutions; iii) which has at least 85% (preferably at least 90%, 95%, 97%, 98% or 99%) identity with SEQ ID NO. 1 or at least 70% (preferably at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99%) of identity with SEQ ID NO. 3; iv) which is produced by the expression of a nucleotide sequence comprising the sequence of SEQ ID NO. 2 or SEQ ID NO. 4; v) which is produced by the expression of a nucleotide sequence that differs from SEQ ID NO. 2 or SEQ ID NO. 4 due to the degeneration of the genetic code; vi) that is produced by the expression of a nucleotide sequence that differs from SEQ ID NO. 2 or SEQ ID NO. 4 by one or more nucleotide additions / insertions, deletions or substitutions; or vii) that is produced by the expression of a nucleotide sequence that is at least 70% (preferably at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99%) identity with SEQ ID NO. 2 or SEQ ID NO. 4.
[000139] Pepsin-resistant alpha amylase can also be encoded by a nucleotide sequence that hybridizes to SEQ ID NO. 2 or SEQ ID NO. 4 under stringent or highly stringent conditions.
[000140] In a preferred embodiment, the amylase for use in the present invention can be one or more of the amylases in one or more of the commercial products below: Commercial product® Company Amylase type Amylase source


[000141] In one embodiment, the amylase can be a maltogenic alpha-amylase from Bacillus (see EP 120 693). This amylase is available for sale under the trade name Novamyl ™ (Novo Nordisk A / S, Denmark). Novamyl is described in detail in the international patent publication WO 91/104669.
[000142] Preferably, amylase is present in the feed in a range of about 50 All / kg to about 10,000 AU / kg of feed, more preferably, about 70 AU / kg of feed at about 7,500 AU / kg of feed, more preferably about 70 AU / kg of feed to about 5,000 AU / kg of feed and more preferably about 100 AU / kg of feed to about 2,000 AU / kg of feed.
[000143] In one embodiment, amylase is present in the feed at more than about 50 AU / kg of feed, suitably, more than about 60 AU / kg of feed, suitably, more than about 70 AU / kg of feed suitably more than about 80 AU / kg of feed, suitably more than about 90 AU / kg of feed, suitably more than about 100 AU / kg of feed.
[000144] In one embodiment, amylase is present in the feed less than about 10,000 AU / kg of feed, suitably, less than about 8,000 AU / kg of feed, suitably, less than about 7,000 AU / kg of feed suitably less than about 5,000 AU / kg of feed, suitably less than about 4,000 AU / kg of feed, suitably less than about 3,000 AU / kg of feed, suitably less than about 2,000 AU / kg of feed.
[000145] Preferably, amylase is present in the feed additive composition in a range of about 10 AU / kg to about 200,000 AU / g of composition, more preferably, about 30 AU / g of composition at about from 100,000 AU / g of composition, and most preferably about 40 AU / g of composition to about 50,000 AU / g of composition, and even more preferably about 50 AU / g of composition at about 20,000 AU / g of composition.
[000146] In one embodiment, amylase is present in the feed additive composition at more than about 10 AU / g of composition, suitably, more than about 20 AU / g of composition, suitably, more than about 30 AU / g of composition, adequately, more than about 40 AU / g of composition, adequately, more than about 50 AU / g of composition.
[000147] In one embodiment, amylase is present in the feed additive composition less than about 200,000 AU / g of composition, suitably, less than about 100,000 AU / g of composition, suitably, less than about 50,000 AU / g of composition, suitably less than about 40,000 AU / g of composition, suitably less than about 30,000 AU / g of composition, suitably less than about 20,000 AU / g of composition .
[000148] It will be understood that an amylase unit (AU) is the amount of enzyme that releases 1 mmol of glycosidic bonds from a polymeric water-insoluble cross-linked starch substrate per minute at pH 6.5 and 37 ° C (this can be called here as the test to determine 1 AU).
[000149] 1 TAU (α-amylase activity) is the amount of enzyme needed to release (in the presence of excess α-glycosidase) 0.20 pmol of glycosidic bonds (expressed as p-nitrophenol equivalents) from a substrate of heptaoside malt per minute at pH 8.0 and 40 ° C. This can be called here the test to determine 1 unit TAU.
[000150] In one embodiment, the enzyme is appropriately classified using the above EC classification, and the EC classification designates an enzyme that has this activity when tested in the assay taught here to determine 1 AU. Protease
[000151] The term protease, as used here, is synonymous with peptidase or proteinase.
[000152] The protease for use in the present invention can be a subtilisin (EC 3.4.21.62) or a bacillolysin (EC 3.4.24.28) or an alkaline serine protease (EC 3.4.21.x) or a keratinase (EC 3.4. XX).
[000153] Preferably, the protease according to the present invention is a subtilisin.
[000154] Suitable proteases include those of animal, vegetable or microbial origin. Mutants obtained by protein engineering or chemically modified are also suitable. The protease can be a serine protease or a metalloprotease, for example, an alkaline microbial protease or trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from Bacillus sp., For example, subtilisin Novo, subtilisin Carlsberg, subtilisin 309 (see, for example, US patent No. 6,287,841), subtilisin 147, and subtilisin 168 (see, for example, WO 89/06279). Examples of trypsin-like proteases are trypsin (for example, of porcine or bovine origin), and Fusarium proteases (see, for example, WO 89/06270 and WO 94/25583). Examples of useful proteases include, but are not limited to, the variants described in WO 92/19729 and WO 98/20115.
[000155] In a preferred embodiment, the protease for use in the present invention can be one or more of the proteases in one or more of the commercial products below:

[000156] In one embodiment, the protease can be a B. subtilis protease.
[000157] In one embodiment, the protease can be a Nocardio-psis protease available from Novozymes A / S.
[000158] Preferably, the protease is present in the feed in a range of about 1,000 U / kg to about 20,000 PLL / kg of feed, more preferably, about 1,500 PU / kg of feed at about 10,000 PU / kg of feed, more preferably, about 2,000 PU / kg of feed to about 6,000 PU / kg of feed.
[000159] In one embodiment, the protease is present in the feed at more than about 1,000 PU / kg of feed, suitably, more than about 1,500 PU / kg of feed, suitably, more than about 2,000 PU / kg of feed .
[000160] In one embodiment, protease is present in the feed less than about 20,000 PU / kg of feed, suitably less than about 10,000 PU / kg of feed, suitably less than about 7,000 PU / kg of feed suitably less than about 6,000 PU / kg of feed.
[000161] Preferably, the protease is present in the feed additive composition in a range of about 200 PU / g to about 400,000 PU / g of composition, more preferably, about 300 PU / g of composition to about 200,000 PU / g of composition, and most preferably about 5,000 PU / g of composition to about 100,000 PU / g of composition, and even more preferably about 700PU / g of composition at about 70,000 PU / g of composition, and even more preferably about 1,000 PU / g of composition to about 60,000 PU / g of composition.
[000162] In one embodiment, the protease is present in the feed additive composition at more than about 200 PU / g of composition, suitably, more than about 300 PU / g of composition, suitably, more than about 400 PU / g of composition, suitably, more than about 500 PU / g of composition, suitably, more than about 750 PU / g of composition, suitably, more than about 1,000 PU / g of composition.
[000163] In one embodiment, the protease is present in the feed additive composition less than about 400,000 PU / g of composition, suitably less than about 200,000 PU / g of composition, suitably less than about 100,000 PU / g of composition, suitably, less than about 80,000 PU / g of composition, suitably, less than about 70,000 PU / g of composition, suitably, less than about 60,000PU / g of composition sition.
[000164] It will be understood that a unit of protease (PU) is the amount of enzyme that releases from the substrate (0.6% casein solution) a microgram of phenolic compound (expressed as tyrosine equivalent) in one minute in pH 7.5 (40mM Na2PO4 buffer / lactic acid) and 40 ° C. This can be called a test to de-terminate 1 PU.
[000165] In one embodiment, the enzyme is appropriately classified using the above EC classification, and the EC classification designates an enzyme that has this activity when tested in the assay taught here to determine 1 PU. Phytase
[000166] Phytase for use in the present invention can be classified as a 6-phytase (classified as 3.1.3.26) or a 3-phytase (classified as E.C. 3.1.3.8).
[000167] In one embodiment, the phytase can be a 6-phytase (E.C. 3.1.3.26).
[000168] In a preferred embodiment, the phytase for use in the present invention can be one or more of the phytases in one or more of the commercial products below:


[000169] The term consensus gene, as used here, means that the DNA vector used to transform the organism contains a synthetic phytase gene based on a consensus sequence, a non-pathogenic yeast Saccharomyces cerevisiae URA gene and the origin of replication of Escherichia coli plasmid pBR322.
[000170] In one embodiment, phytase is a Citrobacter phytase derived, for example, from Citrobacter freundii, preferably C. freundii NCIMB 41247 and its variants, for example, as presented in W02006 / 038062 (incorporated herein, by way of and W02006 / 038128 (incorporated herein by reference), Citrobacter braakii YH-15 as set out in WO 2004/085638, Citrobacter braakii ATCC 51113 as set out in W02006 / 037328 (incorporated by reference), as well as its variants, for example, as presented in W02007 / 112739 (incorporated herein by reference) and WO2011 / 117396 (incorporated herein by reference), Citrobacter amalonaticus, preferably Citrobacter amalonaticus ATCC 25405 or Citrobacter amalonaticus ATCC 25407 as presented in W02006037327 (incorporated herein by reference), Citrobacter gillenii, preferably Citrobacter gillenii DSM 13694 as presented in W02006037327 (here inc. orporado, for reference), or polypeptides of the species Citrobacter intermedius, Citrobacter koseri, Citrobacter murliniae, Citrobacter rodentium, Citrobacter sedlakii, Citrobacter werkmanii, Citrobacter youngae, Citrobacter or its variants.
[000171] In one embodiment, the phytase can be a Citrobacter phytase, for example, Citrobacter freundii, as the phytase enzyme (s) taught in W02006 / 038128, the reference of which is incorporated herein, of reference.
[000172] In preferred embodiments, phytase is preferably E. coli phytase marketed under the name Phyzyme XP ™ by Danisco A / S.
[000173] Alternatively, the phytase can be a Buttiauxella phytase, for example, a Buttiauxella agrestis phytase, for example, the phytase enzymes taught in WO 2006/043178, WO 2008/097619, W02009 / 129489, W02008 / 092901 , PCT / US2009 / 41011 or PCT / IB2010 / 051804, all of which are incorporated by reference.
[000174] In one embodiment, the phytase may be a Hafnia phytase, for example, Hafnia alvei, as the phytase enzyme (s) taught ^) in US2008263688, the reference of which is incorporated herein by way of reference.
[000175] In one embodiment, the phytase can be an Aspirillus phytase, for example, Apergillus orzyae.
[000176] In one embodiment, the phytase can be a penicillium phytase, for example, Penicillium funiculosum.
[000177] Preferably, phytase is present in the feed in a range of about 200 FTU / kg to about 1,000 FTU / kg of feed, more preferably, about 300 FTU / kg of feed at about 750 FTU / kg of feed, more preferably, about 400 FTU / kg of feed to about 500 FTU / kg of feed.
[000178] In one embodiment, phytase is present in the feed at more than about 200 FTU / kg of feed, suitably, more than about 300 FTU / kg of feed, suitably, more than about 400 FTU / kg of feed .
[000179] In one embodiment, phytase is present in the feed less than about 1,000 FTU / kg of feed, suitably, less than about 750 FTU / kg of feed.
[000180] Preferably, phytase is present in the feed additive composition in a range of about 40 FTU / g to about 40,000 FTU / g of composition, more preferably, about 80 FTU / g of composition to about 20,000 FTU / g of composition, and most preferably about 100 FTU / g of composition to about 10,000 FTU / g of composition, and even more preferably about 200 FTU / g of composition at about 10,000 FTU / g composition.
[000181] In one embodiment, phytase is present in the feed additive composition at more than about 40 FTU / g of composition, suitably, more than about 60 FTU / g of composition, suitably, more than about 100 FTU / g of composition, suitably, more than about 150 FTU / g of composition, suitably, more than about 200 FTU / g of composition.
[000182] In one embodiment, phytase is present in the feed additive composition less than about 40,000 FTU / g of composition, suitably less than about 20,000 FTU / g of composition, suitably, less than about 15,000 FTU / g of composition, suitably less than about 10,000 FTU / g of composition.
[000183] It will be understood that, for use in the present invention, 1 FTU (phytase unit) is defined as the amount of enzyme required to release 1 pmol of inorganic orthophosphate from a substrate in one minute under the reaction conditions defined in ISO 2009 phytase assay - A standard assay to determine phytase activity and 1 FTU can be found at International Standard ISO / DIS 30024: 1-17, 2009.
[000184] In one embodiment, the enzyme is appropriately classified using the above EC classification, and the EC classification designates an enzyme that has this activity when tested in the assay taught here to determine 1 FTU. Benefits
[000185] The interaction between DFMs and enzymes is complicated and without sticking to the theory, it is very surprising that we can see an improvement in the individual's resistance to necrotic enteritis, for example, that we see a reduction in injury scores, for example example. Prior to the present invention, the combination of DFMs and enzymes (for example, as taught here) had not been taught for this specific purpose.
[000186] An advantage of the present invention is that the feed additive composition according to the present invention can avoid the negative effects of necrotic enteritis or can be used to improve the individual's resistance to necrotic enteritis.
[000187] Without sticking to the theory, phytase catalyzes the sequential hydrolysis of phytate, the main form of phosphorus storage in cereals and vegetables, for less phosphorylated myo-inositol derivatives with the concomitant release of inorganic phosphate. Phytate hydrolysis causes a reduction in endogenous losses of amino acids to the intestinal lumen. A reduction in the loss of endogenous amino acids in the intestine reduces the availability of nitrogen for the multiplication of bacteria, which helps the activity of DFMs in inhibiting C. perfringens and other pathogenic bacteria.
[000188] Without sticking to the theory, proteases cause nonspecific hydrolysis of dietary protein, generating a variety of polypeptides in the intestinal lumen. The animals finish the hydrolysis of the proteins and absorb the amino acids. However, in the case of enteric pathogenic challenges, pathogenic bacteria can take advantage of the increased availability of peptides in the lumen of the jejunum and ileum. DFMs inhibit the growth of enteropathogens, for example, by competing for N sources, as well as by direct inhibition.
[000189] Furthermore, xylanase degrades the linear polysaccharide be-1,4-xylan into xylose. Without sticking to the theory, the inventors of the present invention showed that the increase in energy digestibility with the combination of DFMs and enzymes is not explained by starch, fat or protein, therefore, it must be explained by non-starch polysaccharides.
[000190] Amylase activity hydrolyzes alpha bonds of large alpha-linked polysaccharides, such as starch, generating dextrins and oligosaccharides, which are absorbed mainly in the small intestine after hydrolysis in maltose and glucose in the gastrointestinal tract wall. Surprisingly, the rapid hydrolysis of starch in the upper digestive tract and the greater absorption of glucose in the duodenum deprives pathogenic bacteria of an important source of energy (glucose) in the jejunum and ileum, which improves DFM activity because of an advantage competitive against pathogens that cannot use pentoses as effectively.
[000191] In combination, the four enzymes and DFMs surprisingly provide a significant improvement over the reduction of pathogens and / or resistance to necrotic enteritis compared to other DFM and combinations of enzymes and / or DFMs alone and / or enzyme (s ) alone.
[000192] The specific combination of DFMs and enzymes taught here can advantageously lead to a reduction in mucin secretion. Without sticking to the theory, this reduced mucin secretion may result in a reduction in the loss of endogenous amino acids and / or may be responsible for improved performance. The specific combination of DFMs and enzymes taught here can advantageously reduce inflammation in the ileum. This can be seen by downregulating the expression of IFR-g in the ileum. The inventors have shown that modulating the immune response can optimize performance. Formulation of DFM with enzymes
[000193] DFM and enzymes can be formulated in any suitable way to ensure that the formulation comprises viable DFMs and active enzymes.
[000194] In one embodiment, DFM and enzymes can be formulated as a liquid, dry powder or granule.
[000195] Dry powder or granules can be prepared by means known to those skilled in the art, such as in an upper spray fluidized bed coating application device, in a lower spray wurster by drum granulation (e.g. granulation high shear), extrusion, drum coating or in a micro-ingredient mixer.
[000196] For some modalities, DFM and / or the enzyme (s) can be coated, for example, encapsulated. Suitably, DFM and enzymes can be formulated within the same coating or can be encapsulated within the same capsule. Alternatively, one or two or three or four of the enzymes can be formulated within the same coating or they can be encapsulated within the same capsule and DFM could be formulated in a coating separate from one or more or all of the enzymes. In some embodiments, such as when DFM is able to produce endospores, DFM can be supplied without any coating. In such circumstances, DFM endospores can simply be mixed with one or two or three or four enzymes. In the latter case, the enzymes can be coated, for example, encapsulated, for example, one or more or all of the enzymes can be coated, for example, encapsulated. Enzymes can be encapsulated as mixtures (i.e., comprising one or more, two or more, three or more or all) of the enzymes or they can be encapsulated separately, for example, as individual enzymes. In a preferred embodiment, all four enzymes can be coated, for example, encapsulated, together.
[000197] In one embodiment, the coating protects enzymes from heat and can be considered a thermal protector.
[000198] In one embodiment, the feed additive composition is formulated into a dry powder or granules, as described in W02007 / 044968 (called TPT granules) or WO1997 / 016076 or WO1992 / 012645 (each of which is incorporated herein as a reference).
[000199] In one embodiment, the feed additive composition can be formulated as a granule for feed compositions comprising: a core; an active agent; and at least one coating, the granule's active agent retaining at least 50% activity, at least 60% activity, at least 70% activity, at least 80% activity after conditions selected from one or more of a) a feed pelletizing process, b) a pre-treatment process of the heated feed with water vapor, c) storage, d) storage as an ingredient in a non-pelleted mixture, and e) storage as an ingredient in a feed mix or a feed premix that comprises at least one compound selected from trace minerals, organic acids, reducing sugars, vitamins, choline chloride, and compounds that result in a feed mix or pre-mix of acid or basic feed.
[000200] With respect to the granule, at least one coating may comprise a moisture-hydrating material that constitutes at least 55% w / w of the granule; and / or at least one coating may comprise two coatings. The two coatings can be a moisture hydration coating and a moisture barrier coating. In some embodiments, the moisture hydration coating can represent between 25% and 60% w / w of the granule and the moisture barrier coating can represent between 2% and 15% w / w of the granule. The moisture hydration coating can be selected from inorganic salts, sucrose, starch, and maltodextrin and the moisture barrier coating can be selected from polymers, gums, whey and starch.
[000201] The granule can be produced using a feed peeling process and the feed pretreatment process can be conducted between 70 ° C and 95 ° C for up to several minutes, such as between 85 ° C and 95 ° Ç.
[000202] In one embodiment, the feed additive composition can be formulated into an animal feed granule comprising: a core; an active agent, the granule's active agent retaining at least 80% activity after storage and after a pelletizing process heated with water vapor where the granule is an ingredient; a moisture barrier coating; and a moisture coating with moisture that represents at least 25% w / w of the granule, the granule having a water activity of less than 0.5 before the pelletizing process heated with water vapor.
[000203] The granule may have a moisture barrier coating selected from polymers and gums and the moisture hydrating material may be an inorganic salt. The moisture hydration coating can represent between 25% and 45% w / w of the granule and the moisture barrier coating can represent between 2% and 10% w / w of the granule.
[000204] The granule can be produced using a skin-heating process heated with water vapor that can be carried between 85 ° C and 95 ° C for up to several minutes.
[000205] In some embodiments, DFM (for example, endoscopes of DFM) can be diluted using a diluent, such as starch powder, limestone or similar.
[000206] In one embodiment, the composition is in a liquid formulation suitable for consumption, preferably, such liquid for consumption contains one or more of the following: a buffer, salt, sorbitol and / or glycerol.
[000207] In another embodiment, the feed additive composition can be formulated by applying, for example, sprinkling, the enzyme (s) on a carrier substrate, such as crushed wheat, for example.
[000208] In one embodiment, the feed additive composition according to the present invention can be formulated as a premix. Just as an example, the premix may comprise one or more feed components, such as one or more minerals and / or one or more vitamins.
[000209] In one embodiment, the DFM and / or enzymes for use in the present invention are formulated with at least one physiologically acceptable carrier selected from at least one of mal-todextrin, limestone (calcium carbonate), cyclodextrin , wheat or a component of wheat, sucrose, starch, Na2SO4, talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, nitrate, phosphate, calcium, metabisulfite, formate and mixtures thereof. Packing
[000210] In one embodiment, the feed additive and / or premix composition and / or animal feed or food according to the present invention is packaged.
[000211] In a preferred embodiment, the composition of feed additive and / or premix and / or animal feed or food is packaged in a bag, like a paper bag.
[000212] In an alternative embodiment, the composition of feed additive and / or premix and / or animal feed or food can be sealed in a container. Any suitable container can be used. Ration
[000213] The feed additive composition of the present invention can be used as - or in the preparation of - a feed.
[000214] The term "feed" is used as a synonym for "animal feed".
[000215] The feed can be in the form of a solution or as a solid - depending on the use and / or mode of application and / or mode of administration.
[000216] When used as - or in the preparation of - a feed - as a functional feed - the composition of the present invention can be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient , a nutritionally acceptable adjuvant, a nutritionally active ingredient.
[000217] In a preferred embodiment, the feed additive composition of the present invention is mixed with a feed component to form a feed.
[000218] The term "feed component" for use in the present invention, means all or part of the feed. Part of the feed may mean one constituent of the feed or more than one constituent of the feed, for example, 2 or 3 or 4. In one embodiment, the term "feed component" encompasses a premix or premix constituents.
[000219] Preferably, the feed may be a forage, or a pre-mix, a compound feed, or a pre-mix. In one embodiment, the feed additive composition according to the present invention can be mixed with a compound feed, a compound feed component or a premix of a compound feed or a forage, forage component, or a premixing of a forage.
[000220] The term forage, for use in the present invention, means any food that is provided to an animal (instead of the animal having to fetch the food alone). The forage includes plants that have been cut.
[000221] The term forage includes hay, straw, silage, compacted and pelleted feed, oils and mixed feed and also sprouted grains and vegetables.
[000222] Fodder can be obtained from one or more of the plants selected from: alfalfa (lucerne), barley, itching, brassicas, Chau moellier, kale, rapeseed (canola), rutabaga (swede turnip), turnip, clover, hybrid clover, red clover, underground clover, white clover, grass, rocker, fescue, grasses of the Bermuda group, brome, common grass, meadow grasses (naturally mixed pasture lawns, orchard grass, rye grass , Timothy grass, corn (more), millet, oats, sorghum, soybeans, trees (hay pruning tree shoots), wheat, and vegetables.
[000223] The term "compound feed" means commercial feed in the form of flour, pellet, rings, cake or bran. Compound feeds can be mixed from various raw materials and additives. These mixtures are formulated according to the specific requirements of the target animal.
[000224] Compound diets can be complete diets that provide all the necessary nutrients daily, concentrates that provide a portion of the portion (protein, energy) or supplements that provide only additional micronutrients, such as minerals and vitamins.
[000225] The main ingredients used in compound feed are feed grains, which include corn, soybeans, sorghum, oats and barley.
[000226] Suitably, a premix, as called here, can be a composition composed of micro-ingredients such as vitamins, minerals, chemical preservatives, antibiotics, fermentation products, and other essential ingredients. Pre-mixes are generally compositions suitable for mixing in commercial feeds.
[000227] Any feed of the present invention may comprise one or more feed materials selected from the group comprising a) cereals, such as small grains (for example, wheat, barley, rye, oats and combinations thereof) and / or grains large, such as corn or sorghum; b) cereal by-products, such as corn gluten flour, dry distillery grain soluble (DDGS), wheat fiber, wheat bran, wheat cuts, rice bran, rice husks, oat husks, palm kernels , and pulp of citrus fruits; c) protein obtained from sources such as soy, sunflower, peanut, lupine, peas, broad beans, cotton, canola, fish meal, dry plasma protein, meat and bone meal, potato protein, whey, copra, sesame ; d) oils and fats obtained from plant and animal sources; e) minerals and vitamins.
[000228] A feed of the present invention may contain at least 30%, at least 40%, at least 50% or at least 60%, by weight of corn and soy bean bran or corn and whole soy, or wheat bran or sunflower bran.
[000229] Furthermore or alternatively, a feed of the present invention may comprise at least one feed material with a high fiber content and / or at least one by-product of at least one feed material with a high fiber content to provide a high fiber content. Examples of high fiber feed materials include: wheat, barley, rye, oats, cereal by-products such as corn gluten flour, distillery dry grain solubles (DDGS), wheat fiber, wheat bran, cuts wheat, rice bran, rice husks, oat husks, palm kernels, and citrus pulp. Some sources of protein can also be considered to have a high fiber content: protein obtained from sources such as sunflower, lupine, broad beans and cotton.
[000230] In the present invention, the feed may be one or more of the following: a compound and premixed feed, including pellets, rings or bolus (bovine); a crop or crop residue: corn, soybeans, sorghum, oats, barley, maize fodder, copra, straw, mill, sugar beet craving; Fish's flour; fresh cut grass and other forage plants; meat and bone meal; molasses; solid oilseed residue and pressed cake; oligosaccharides; conserved forage plants: hay and silage; seaweed; seeds and grains, whole or prepared by crushing, grinding, etc .; sprouted grains and vegetables; Yeast extract.
[000231] The term ration in the present invention also encompasses, in some embodiments, pet food. A pet food is a plant or animal material intended for consumption by pets, such as dog food or cat food. Pet food, such as food for dogs and cats, can be in a dry form, such as in pieces for dogs, or in a wet canned form. Cat food may contain the amino acid taurine.
[000232] The term ration in the present invention also encompasses, in some embodiments, fish food. A fish food normally contains the macronutrients, trace elements and vitamins needed to keep fish in captivity in good health. The fish food can be in the form of a flake, pellet or pill. Pelleted shapes, some of which sink quickly, are often used for larger fish or bottom-fed species. Some fish foods also contain additives, such as beta carotene or sex hormones, to artificially improve the color of ornamental fish.
[000233] The term feed in the present invention also encompasses, in some embodiments, bird food. Bird food includes food that is used in bird feeders and to feed pet birds. Typically, bird food comprises a variety of seeds, but can also cover tallow (beef or lamb fat).
[000234] For use in the present invention, the term "putting in contact" refers to the indirect or direct application of the composition of the present invention to the product (for example, the feed). Examples of the application methods that can be used include, but are not limited to, treating the product in a material comprising the feed additive composition, direct application by mixing the feed additive composition with the product, spraying of the feed additive composition on the product surface or immersing the product in a preparation of the feed additive composition.
[000235] In one embodiment, the feed additive composition of the present invention is preferably mixed with the product (for example, feed). Alternatively, the feed additive composition can be included in the emulsion or raw ingredients of a feed.
[000236] For some applications, it is important that the composition is made available on or on the surface of a product to be affected / treated. This allows the composition to confer one or more of the following favorable characteristics: performance benefits.
[000237] The feed additive compositions of the present invention can be applied to interweave, coat and / or impregnate a product (e.g., feed or raw feed ingredients) with a controlled amount of DFM and enzymes.
[000238] DFM and enzymes can be used simultaneously (for example, when they are mixed together or even when they are released by different routes) or sequentially (for example, they can be released by different routes). In one embodiment, preferably, DFM and enzymes are applied simultaneously. Preferably, the DFM and the enzymes are mixed before being released to a feed or a raw feed ingredient.
[000239] DFM in feed additive compositions according to the present invention - can be added in suitable concentrations - as, for example, in concentrations in the final feed product that offer a daily dose between about 2x105 CFU at about 2x1011 UFC, suitably, between about 2x106 to about 1x1010, suitably, between about 3.75x107 UFC to about 1x1O10 UFC.
[000240] Preferably, the feed additive composition of the present invention will be thermally stable to heat treatment up to about 70 ° C; up to about 85 ° C; or up to about 95 ° C. Heat treatment can be done for up to about 1 minute; up to about 5 minutes; up to about 10 minutes; up to about 30 minutes; up to about 60 minutes. The term thermally stable means that at least about 75% of the enzyme and / or DFM components that were present / active in the additive before heating to the specified temperature are still present / active after it has cooled to temperature environment. Preferably, at least about 80% of the enzymatic and / or DFM components that were present and active in the additive before heating to the specified temperature are still present and active after it has cooled to room temperature.
[000241] In a particularly preferred embodiment, the feed additive composition is homogenized to produce a powder.
[000242] In an alternative preferred embodiment, the feed additive composition is formulated as granules, as described in W02007 / 044968 (called TPT granules) incorporated herein by way of reference.
[000243] In another preferred embodiment, when the feed additive composition is formulated in granules, the granules comprise a hydrated barrier salt applied as a coating on the protein core. The advantage of such a saline coating is improved thermal tolerance, improved storage stability and protection against other feed additives that would otherwise have adverse effects on the enzyme and / or DFM.
[000244] Preferably, the salt used for the saline coating has a water activity greater than 0.25 or constant humidity greater than 60% at 20 ° C.
[000245] Preferably, the saline coating comprises Na2SO4.
[000246] The method for preparing a feed additive composition may also comprise the additional step of pelletizing the powder. The powder can be mixed with other components known in the art. The powder, or mixture comprising the powder, can be forced through a matrix and the resulting tapes are cut into suitable pellets of varying length.
[000247] Optionally, the pelletizing stage may include a treatment with water vapor, or a conditioning stage, before the formation of the pellets. The mixture comprising the powder can be placed in a conditioner, for example, a mixer with water vapor injection. The mixture is heated in the conditioner to a specified temperature, such as from 60 to 100 ° C, typical temperatures would be 70 ° C, 80 ° C, 85 ° C, 90 ° C or 95 ° C. The residence time can vary from seconds to minutes and even hours. For example, 5 seconds, 10 seconds, 15 seconds, 30 seconds, 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes and 1 hour.
[000248] It will be understood that the feed additive composition of the present invention is suitable for addition to any suitable feed material.
[000249] As used here, the term feed material refers to the basic feed material that will be consumed by an animal. It will be further understood that it can comprise, for example, at least one or more unprocessed grains, and / or processed plant and / or animal material, such as soybean meal or bone meal.
[000250] As used here, the term "feed" refers to a feed material to which one or more feed additive compositions have been added.
[000251] It will be understood by those skilled in the art that different animals require different rations, and even the same animal may require different rations, depending on the purpose for which the animal is bred.
[000252] Preferably, the feed may comprise feed materials comprising corn or maize, wheat, barley, triticale, rye, rice, tapioca, sorghum, and / or any of the by-products, as well as protein-rich components such as bean bran soybeans, rapeseed meal, canola meal, cottonseed meal, sunflower seed meal, animal by-product meal and mixtures thereof. Most preferably, the feed may comprise animal fats and / or vegetable oils.
[000253] Optionally, the feed may also contain additional minerals, such as calcium and / or additional vitamins.
[000254] Preferably, the feed is a mixture of soybean meal and corn.
[000255] In one embodiment, preferably, the feed is not food for pets.
[000256] In another aspect, a method for producing a feed is presented. The feed is typically produced in feed mills in which the raw materials are first ground to a suitable particle size and then mixed with suitable additives. The feed can then be produced as a mass or as pellets; the latter typically involves a method by which the temperature is raised to a target level and then the feed is passed through a matrix to produce pellets of a particular size. Pellets are cooled naturally. Subsequently, liquid additives like fat and enzyme can be added. Feed production may also involve an additional step that includes extrusion or expansion before pelletizing - in particular, by suitable techniques that may include at least the use of water vapor.
[000257] The feed can be a feed for a monogastric animal, such as poultry (for example, poultry, laying hens, chicken breeders, turkey, duck, goose, waterfowl), pigs (all age categories), a pet (eg dogs, cats) or fish, preferably the feed is for poultry.
[000258] In one modality, the ration is not for a laying hen.
[000259] Just as an example, a chicken feed, for example, chickens intended for food, may comprise one or more of the ingredients mentioned in the table below, for example, in the percentages given in the table below:

[000260] Just as an example, the specification of the diet for chickens, such as chickens intended for feeding, can be as stipulated in the table below:


[000261] Just as an example, a diet for laying hens can comprise one or more of the ingredients mentioned in the table below, for example, in the percentages given in the table below:

[000262] Just as an example, the diet specification for laying hens can be as stipulated in the table below:

[000263] Just as an example, a turkey feed can comprise one or more of the ingredients mentioned in the table below, for example, in the percentages given in the table below:

[000264] Just as an example, the specification of the diet for turkeys can be as stipulated in the table below:

[000265] Just as an example, a piglet feed may comprise one or more of the ingredients mentioned in the table below, for example, in the percentages given in the table below:

[000266] Just as an example, the specification of the diet for piglets can be as stipulated in the table below:

[000267] Just as an example, a feed for growing / finishing pigs can comprise one or more of the ingredients mentioned in the table below, for example, in the percentages given in the table below:

[000268] Just as an example, the specification of the diet for growing / finishing pigs can be as stipulated in the table below:

[000269] The feed additive composition of the present invention and other components and / or the feed comprising it can be used in any suitable form.
[000270] The feed additive composition of the present invention can be used in the form of solid or liquid or alternative preparations thereof. Examples of solid preparations include powders, large pills, capsules, pellets, tablets, dust, and granules that can be wettable, spray dried or freeze dried. Examples of liquid preparations include, but are not limited to, aqueous, organic or aqueous-organic solutions, suspensions and emulsions.
[000271] In some applications, DFM or the feed additive compositions of the present invention can be mixed with feed or administered in drinking water. In one embodiment, the dosage range for inclusion in water is about 1x103 UFC / animal / day to about 1x101 ° UFC / animal / day, and more preferably, about 1x107 UFC / animal / day.
[000272] Suitable examples of forms include one or more of: powders, pastes, large pills, pellets, tablets, pills, capsules, eggs, solutions or suspensions, which may contain flavoring or coloring agents, for immediate release applications, delayed, modified, sustained, pulsed or controlled.
[000273] As an example, if the composition of the present invention is used in a solid, for example, pelleted form, it can also contain one or more of: excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine; disintegrators such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates; granulation binders such as polyvinyl pyrrolidone, hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), sucrose, gelatin and acacia; lubricating agents such as magnesium stearate, stearic acid, glyceryl beenate and talc may be included.
[000274] Examples of nutritionally acceptable vehicles for use in the preparation of forms include, for example, water, saline solutions, alcohol, silicone, waxes, petroleum gel, vegetable oils, polyethylene glycols, propylene glycol, liposomes, sugars, gelatin , lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, essential oil, fatty acid monoglycerides and diglycerides, petroetral fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidone, and the like.
[000275] Preferred excipients for the forms include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols.
[000276] For aqueous suspensions and / or elixirs, the composition of the present invention can be combined with various sweetening or flavoring agents, dyeing or coloring matters, with emulsifying and / or suspending agents and with diluents such as water, propylene glycol and glycerin , and combinations thereof.
[000277] Non-hygroscopic whey is often used as a vehicle for DFMs (particularly, bacterial DFMs) and is a good way to start growth.
[000278] Pastes containing bacterial DFM can be formulated with vegetable oil and inert gelling ingredients.
[000279] Fungal products can be formulated with grain by-products as vehicles.
[000280] In one embodiment, preferably, the feed additive composition according to the present invention is not in the form of a microparticle system, such as the microparticle system taught in W02005 / 123034. Administration
[000281] The DFM and / or feed additive composition according to the present invention can be designed for single administration or can be designed for daily feeding.
[000282] The optimum amount of the composition (and each component present in it) to be used in the combination of the present invention will depend on the product to be treated and / or the method of contacting the product with the composition and / or the intended use for it.
[000283] The amount of DFM and enzymes used in the compositions must be sufficient to be effective and remain sufficiently effective in improving the performance of the feed products given to the animal containing said composition. This period of time for effectiveness must extend to at least the time of use of the product (for example, composition of feed additive or feed containing it).
[000284] The ratio between DFM and each enzyme in the feed can be in the ranges given below:
[000285] DFM: phytase (UFC / FTU): In the range of 5.0x102 UFC of DFM: 1FTU of enzyme to 5.0x109 UFC: 1FTU of enzyme; preferably, in the range of 7.5x104 CFU of DFM: 1FTU of enzyme to 2.5x107 CFU: 1FTU of enzyme.
[000286] DFM: xylanase (CFU / XU): In the range of 6.25x101 CFU of DFM: 1XU of enzyme to 2.0x109 CFU: 1XU of enzyme; preferably, in the range of 1.88x104CFU of DFM: 1XU of enzyme to 1.0x107 CFU: 1XU of enzyme.
[000287] DFM: amylase (CFU / AU): In the range of 1.0x102 CFU of DFM: 1AU of enzyme to 2.0x101 ° CFU: 1AU of enzyme; preferably, in the range of 3.7x104CFU of DFM: 1AU of enzyme to 1.0x108 CFU: 1AU of enzyme.
[000288] DFM: protease (CFU / PU): In the range of 5.0x101 UFC of DFM: 1PU of enzyme to 1.0x109 CFU: 1PU of enzyme; preferably, in the range of 1.25x104 CFU of DFM: 1PU of enzyme to 5.0x106 CFU: 1PU of enzyme.
[000289] In one embodiment, the feed preferably comprises the following: a protease at least 4,000 PU / kg of feed; a xylanase at least 1,000 XU / kg to 2,000 XU / kg of feed (for example Avizyme at 1,000 XU / kg of feed or Axtra XAP at least 2,000 XU / kg of feed); an amylase; at least 1,800 AU / kg or 200 TAU / kg of feed (for example, Avizyme at 1,800 AU / kg or Axtra XAP at least 200 TAU / kg of feed); a phytase at least 500 FTU / kg of feed; and Envivo Pro (DFM) at least 75,000 CFU / g to 150,000 CFU / g of feed.
[000290] In one embodiment, the feed preferably comprises the following: a protease at 4,000 PU / kg of feed; a xylanase at 1,000 XU / kg at 2,000 XU / kg of feed (eg Avizyme at 1,000 XU / kg of feed or Axtra XAP at 2,000 XU / kg of feed); an amylase; 1,800 AU / kg or 200 TAU / kg of feed (for example Avizyme at 1,800 AU / kg or Axtra XAP at 200 TAU / kg of feed); a phytase at 500 FTU / kg of feed; and Envivo Pro (DFM) at 75,000 CFU / g to 150,000 CFU / g of feed.
[000291] In one embodiment, the feed preferably comprises the following: a protease at 5,000 PU / kg of feed; a xylanase at 1,250 XU / kg at 2,500 XU / kg of feed (for example, Avizyme at 1,000 XU / kg of feed or Axtra XAP at 2,500 XU / kg of feed); an amylase; 2,250 AU / kg or 250 TAU / kg of feed (for example, Avizyme at 1,800 AU / kg or Axtra XAP at 250 TAU / kg of feed); a phytase at 625 FTU / kg of feed; and Envivo Pro (DFM) at 75,000 CFU / g to 150,000 CFU / g of feed.
[000292] In another embodiment, the feed comprises the following: a protease at 2,000 PU / kg of feed; a xylanase at 500 XU / kg at 1,000 XU / kg of feed (for example, Avizyme at 500 XU / kg of feed or Axtra XAP at 1,000 XU / kg of feed); an amylase; 900 AU / kg or 100 TAU / kg of feed (for example, Avizyme at 900 AU / kg or Axtra XAP at 100 TAU / kg of feed); a phytase at 500 FTU / kg of feed; and Envivo Pro (DFM) at 37,500 CFU / g to 75,000 CFU / g of feed.
[000293] In a preferred embodiment, the feed additive composition comprises sufficient enzyme and DFMs to administer the feed as follows: a protease at 4,000 PU / kg of feed; a xylanase at 1,000 XU / kg at 2,000 XU / kg of feed (for example, Avizyme at 1,000 XU / kg of feed or Axtra XAP at 2000 XU / kg of feed); an amylase; 1,800 AU / kg or 200 TAU / kg of feed (for example Avizyme at 1,800 AU / kg or Axtra XAP at 200 TAU / kg of feed); a phytase at 500 FTU / kg of feed; and Envivo Pro (DFM) at 75,000 CFU / g to 150,000 CFU / g of feed.
[000294] In a preferred embodiment, the feed additive composition comprises sufficient enzyme and DFMs to administer the feed as follows: a protease at 2,000 PU / kg of feed; a xylanase at 500 XU / kg at 1,000 XU / kg of feed (for example, Avizyme at 500 XU / kg of feed or Axtra XAP at 1,000 XU / kg of feed); an amylase; 900 AU / kg or 100 TAU / kg of feed (for example, Avizyme at 900 AU / kg or Axtra XAP at 100 TAU / kg of feed); a phytase at 500 FTU / kg of feed; and Envivo Pro (DFM) at 37,500 CFU / g to 75,000 CFU / g of feed. Combination with other components
[000295] DFM and the enzyme (s) for use in the present invention can be used in combination with other components. Thus, the present invention also relates to combinations. DFM in combination with a protease, xylanase, amylase and phytase can be referred to in the present invention as "the feed additive composition of the present invention".
[000296] The combination of the present invention comprises the feed additive composition of the present invention (or one or more of its constituents) and another component that is suitable for animal consumption and is capable of providing a medical or physiological benefit to the consumer.
[000297] In one embodiment, preferably, the "other component" is not an additional enzyme or an additional DFM.
[000298] The components can be prebiotics. Prebiotics are typically non-digestible carbohydrates (oligo- or polysaccharides) or a sugar alcohol that is not degraded or absorbed in the upper digestive tract. Known prebiotics used in commercial and useful products according to the present invention include inulin (fructo-oligosaccharide, or FOS) and transgalacto-oligosaccharide (GOS or TOS). Suitable prebiotics include palatinose oligosaccharide, soybean oligosaccharide, alginate, xanthan, pectin, al-farrobeira gum (LBG), inulin, guar gum, galacto-oligosaccharide (GOS), fructo-oligosaccharide (FOS), non-degradable starch, lactose , lactulose, lactitol, maltitol, maltodextrin, polydextrose (ie Litesse®), lactitol, lactosaccharose, soybean oligosaccharides, palatine, isomaltooligosaccharides, gluco-oligosaccharides and xylooligosaccharides, dietary fiber, fragments of dietary fiber mannan-oligosaccharides.
[000299] Dietary fibers may include non-starch polysaccharides, such as arabinoxylans, cellulose and many other plant components, such as resistant dextrins, inulin, lignin, waxes, chitins, pectins, beta-glucans and oligosaccharides.
[000300] In one embodiment, the present invention relates to combining the feed additive composition according to the present invention (or one or more of its constituents) with a prebiotic. In another embodiment, the present invention relates to a feed additive composition that comprises (or consists essentially of or consists of) a DFM in combination with a xylanase, an amylase, a phytase, a protease and a prebiotic.
[000301] The prebiotic can be administered simultaneously with (for example, in mixture with or released simultaneously by the same route or by different routes) or sequentially to the (for example, the same or different routes) feed additive composition (or constituents) according to the present invention.
[000302] Other components of the combinations of the present invention include polydextrose, such as Litesse®, and / or a maltodextrin and / or lactitol. These other components can be added, optionally, to the feed additive composition to aid the drying process and help the survival of the DFM.
[000303] Additional examples of other suitable components include one or more of: thickeners, gelling agents, emulsifiers, binders, crystal modifiers, sweeteners (including artificial sweeteners), rheology modifiers, stabilizers, anti-oxidants, dyes, enzymes , carriers, vehicles, excipients, thinners, lubricating agents, flavoring agents, pretending matter, suspending agents, disintegrators, granulation binders, etc. These other components can be natural. These other components can be prepared using chemical and / or enzymatic techniques.
[000304] In one embodiment, DFM and / or enzymes can be encapsulated. In one embodiment, the composition of feed additive and / or DFM and / or enzymes is / are formulated (s) as a dry powder or granule, as described in W02007 / 044968 (called TPT granules) - reference incorporated herein as a reference.
[000305] In a preferred embodiment, DFM and / or enzymes for use in the present invention can be used in combination with one or more lipids.
[000306] For example, DFM and / or enzymes for use in the present invention can be used in combination with one or more lipid mice. The lipid micelle can be a simple lipid micelle or a complex lipid micelle.
[000307] The lipid micelle can be an aggregate of molecules originating from antipathetic substances, such as a lipid and / or an oil.
[000308] For use in the present invention, the term "thickening or gelling agent" refers to a product that avoids separation by reducing or preventing the movement of particles, droplets of immiscible liquids, air or insoluble solids. Thickening occurs when individual hydrated molecules cause an increase in viscosity, reducing the speed of separation. Gelation occurs when hydrated molecules bond to form a three-dimensional network that traps the particles, thus immobilizing them.
[000309] The term "stabilizer" as used here, is defined as an ingredient or combination of ingredients that prevents a product (for example, a feed product) from changing over time.
[000310] The term "emulsifier", as used here, refers to an ingredient (for example, a feed ingredient) that prevents the separation of emulsions. Emulsions are two immiscible substances, one present in the form of a droplet, contained within the other. Emulsions can consist of oil in water, where the droplet or dispersed phase is oil and the continuous phase is water; or water in oil, where the water becomes the dispersed phase and the continuous phase is oil. Foams, which are gas-in-liquid, and suspensions, which are solid-in-liquid, can also be stabilized through the use of emulsifiers.
[000311] For use in the present invention, the term "binder" refers to an ingredient (for example, a feed ingredient) that binds the product together through a physical or chemical reaction. During "gelling", for example, water is absorbed, providing a binding effect. However, binders can absorb other liquids, such as oils, keeping them inside the product. In the context of the present invention, binders would typically be used in solid or low moisture products, for example, baking products: cakes, donuts, bread and the like.
[000312] "Carriers" or "vehicles" means materials suitable for the administration of DFM and / or enzymes and include any of these materials known in the art such as, for example, any liquid, gel, solvent, liquid diluent, solubilizers, or the like, which is non-toxic and does not interact with any component of the composition in a harmful way.
[000313] The present invention provides a method for preparing a feed additive composition which comprises mixing a DFM and a xylanase, a protease, a phytase and an amylase with at least one physiologically acceptable vehicle selected from at least one among maltodextrin , limestone (calcium carbonate), cyclodextrin, wheat or a component of wheat, sucrose, starch, Na2SO4, talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1,3-propane diol, glucose , parabens, sodium chloride, citrate, nitrate, phosphate, calcium, metabisulfite, formate and mixtures thereof.
[000314] Examples of excipients include one or more of: microcrystalline cellulose and other celluloses, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine, starch, milk sugar and high molecular weight polyols.
[000315] Examples of disintegrants include one or more of: starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates.
[000316] Examples of granulation binders include one or more of: polyvinyl pyrrolidone, hydroxy-propyl-methyl cellulose (HPMC), hydroxy-propyl-cellulose (HPC), sucrose, maltose, gelatin and acacia.
[000317] Examples of lubricating agents include one or more of: magnesium stearate, stearic acid, glyceryl beenate and talc.
[000318] Examples of diluents include one or more of: water, ethanol, propylene glycol and glycerin, and combinations thereof.
[000319] The other components can be used simultaneously (for example, when they are mixed together or even when they are released by different routes) or sequentially (for example, they can be released by different routes).
[000320] Preferably, when the feed additive composition of the present invention is mixed with other component (s), DFM remains viable.
[000321] In one embodiment, preferably, the feed additive composition according to the present invention does not comprise chromium or organic chromium.
[000322] In one embodiment, preferably, the feed additive according to the present invention does not contain glucanase.
[000323] In one embodiment, preferably, the feed additive according to the present invention does not contain ascorbic acid. Concentrates
[000324] DFMs for use in the present invention can be in the form of concentrates. Typically, these concentrates comprise a substantially high concentration of a DFM.
[000325] The feed additive compositions according to the present invention can have a viable cell content (colony forming units, UFCs) that is in the range of at least 104 UFC / g (suitably, including at least 105 UFC / g, such as at least 106 UFC / g, for example, at least 107 UFC / g, at least 108 UFC / g, for example, at least 109 UFC / g) at about 1010 UFC / g (or even about 1011 UFC / g or about 1012 UFC / g).
[000326] When DFM is in the form of a concentrate, the feed additive compositions according to the present invention can have a viable cell content in the range of at least 109 CFU / g to about 1012 CFU / g, from preferably at least 1010 UFC / g about 1012 UFC / g.
[000327] Powders, granules and liquid compositions in the form of concentrates can be diluted with water or resuspended in water or other suitable diluents, for example, a suitable growth medium such as milk or mineral or vegetable oils, to provide ready-made compositions For use.
[000328] The DFM or feed additive composition of the present invention or the combinations of the present invention in the form of concentrates can be prepared according to methods known in the art.
[000329] In one aspect of the present invention, the enzymes or feed is brought into contact with a composition in a concentrated form.
[000330] The compositions of the present invention can be spray dried or freeze dried using methods known in the art.
[000331] Typical processes for making particles using an atomization drying process involve a solid material that is dissolved in a suitable solvent (for example, a culture of a DFM in a fermentation medium). Alternatively, the material can be suspended or emulsified in a non-solvent to form a suspension or emulsion. Other ingredients (as discussed above) or components, such as microbicidal agents, stabilizing agents, dyes and agents that aid the drying process can optionally be added at this stage.
[000332] The solution is then atomized to form a fine mist of droplets. The droplets immediately enter a drying chamber where they come in contact with a drying gas. The solvent is evaporated from the droplets into the drying gas to solidify the droplets, thus forming particles. The particles are then separated from the drying gas and collected. Individual
[000333] The term "individual", as used herein, means an animal that will be or has been administered with a feed additive composition according to the present invention or a feed comprising said feed additive composition according to present invention.
[000334] The term "individual", as used here, means an animal. Preferably, the individual is a mammal, bird, fish or crustacean that includes, for example, cattle or a domesticated animal (for example, a pet).
[000335] In one embodiment, the "individual" is cattle.
[000336] The term "livestock", as used here, refers to any farm animal. Preferably, livestock is one or more of cows or bulls (including, calves), poultry, pigs (including, piglets), poultry (including broilers, chickens and turkeys), poultry, fish (including, water fish sweet, such as salmon, cod, trout and carp, for example, Chinese carp, and marine fish, such as sea bass), crustaceans (such as shrimp, mollusks and scallops), horses (including, racehorses), sheep (including, lambs).
[000337] In one embodiment, the term cattle and / or poultry and / or chickens does not include laying birds.
[000338] In another embodiment, the "individual" is a domesticated animal or pet or an animal kept in a zoo.
[000339] The term "domesticated animal or pet or animal kept in a zoo" as used here, refers to any relevant animal that includes canines (e.g., dogs), felines (e.g., cats), rodents ( for example, guinea pigs, rats, mice), birds, fish (including freshwater fish and sea fish), and horses.
[000340] In one embodiment, the individual may be stimulated by an enteric pathogen.
[000341] As an example, an individual may have one or more enteric pathogens present in his gastrointestinal tract or di-gestational tract. For example, an individual may have one or more enteric pathogens in his gastrointestinal tract or digestive tract at a level that: i) results in loss of animal performance and / or ii) is at clinically relevant levels; or iii) is at subclinical levels.
[000342] The enteric pathogen can be Clostridium perfringens, for example. Performance
[000343] As used here, "animal performance" can be terminated by the feed efficiency and / or weight gain of the animal and / or the feed conversion ratio and / or the digestibility of a nutrient in a feed ( for example, digestibility of amino acids) and / or digestible energy or metabolizable energy in a feed and / or by nitrogen retention and / or by the animals' ability to avoid the negative effects of necrotic enteritis and / or by the individual's immune response.
[000344] Preferably "animal performance" is determined by the feed efficiency and / or weight gain of the animal and / or the feed conversion ratio.
[000345] By "improved animal performance" is meant that there is increased feed efficiency, and / or increased weight gain and / or reduced feed conversion ratio and / or nutrient digestibility or improved energy in a feed and / or improved nitrogen retention and / or enhanced ability to avoid the negative effects of necrotic enteritis and / or an enhanced immune response in the individual resulting from the use of the feed additive composition of the present invention in the feed compared to the feed that does not include the said feed additive composition.
[000346] Preferably, "improved animal performance" means that there is increased feed efficiency and / or increased weight gain and / or reduced feed conversion ratio.
[000347] As used here, the term "feed efficiency" refers to the amount of weight gain in an animal that occurs when the animal is fed at will or a specified amount of food over a period of time.
[000348] By "increased feed efficiency" is meant that the use of a feed additive composition according to the present invention in the feed results in an increased weight gain per unit of feed intake compared to an animal fed without said feed additive composition. Feed conversion ratio (FCR)
[000349] As used here, the term "feed conversion ratio" refers to the amount of feed given to an animal to increase the animal's weight by a specified amount.
[000350] An improved feed conversion ratio means a lower feed conversion ratio.
[000351] By "lower feed conversion ratio" or "improved feed conversion ratio" is meant that the use of a feed additive composition in a feed results in a smaller amount of feed having to be given to an animal to increase the weight of the animal by a specified amount compared to the amount of feed necessary to increase the weight of the animal by the same amount, when the feed does not comprise said feed additive composition. Digestibility of nutrients
[000352] The digestibility of nutrients, as used here, means the fraction of a nutrient that disappears from the gastrointestinal tract or a specified segment of the gastrointestinal tract, for example, the small intestine. The digestibility of nutrients can be measured as the difference between what is administered to the individual and what comes out in the individual's stool, or between what is administered to the individual and what remains in digestion in a specified segment of the gastro-intestinal tract, for example, the ileum.
[000353] The digestibility of nutrients, as used here, can be measured by the difference between the intake of a nutrient and the nutrient excreted through the total collection of excrement over a period of time; or with the use of an inert marker that is not absorbed by the animal, and allows the researcher to calculate the amount of the nutrient that has disappeared throughout the gastrointestinal tract or a segment of the gastrointestinal tract. Such an inert marker can be titanium dioxide, chromic oxide or acid insoluble ash. Digestibility can be expressed as a percentage of the nutrient in the feed, or as units of mass of digestible nutrient per unit of nutrient mass in the feed.
[000354] Nutrient digestibility, as used here, encompasses starch digestibility, fat digestibility, protein digestibility and amino acid digestibility.
[000355] Energy digestibility, as used here, means the gross energy of the feed consumed minus the gross energy of the stool or the gross energy of the feed consumed minus the gross energy of the digestion material remaining in a specified segment of the gastro-intestinal tract of the animal, for example, the ileum. Metabolizable energy, as used here, refers to the apparent metabolizable energy and means the gross energy of the feed consumed minus the gross energy contained in faeces, urine, and gaseous products of digestion. Energy digestibility and metabolizable energy can be measured as the difference between raw energy intake and gross energy excreted in the stool or digestion material present in a specified segment of the gastrointestinal tract using the same methods to measure nutrient digestibility , with appropriate corrections for nitrogen excretion to calculate the metabolizable energy of the feed. Nitrogen retention
[000356] Nitrogen retention, as used here, means an individual's ability to retain nitrogen from the diet as body weight. A negative nitrogen balance occurs when the excretion of nitrogen exceeds the daily intake and is often seen when the muscle is being lost. A positive nitrogen balance is often associated with muscle growth, particularly in growing animals.
[000357] Nitrogen retention can be measured as the difference between nitrogen intake and nitrogen excreted through the total collection of excrement and urine over a period of time. It is understood that the excreted nitrogen includes undigested protein from the feed, endogenous proteinaceous secretions, microbial protein, and urinary nitrogen. Survival
[000358] The term survival, as used here, means the number of individuals who remain alive. The term "improved survival" can be another way of saying "reduced mortality". Carcass yield and meat yield
[000359] The term carcass yield, as used here, means the amount of carcass as a proportion of live body weight, after a commercial or experimental slaughter process. The term carcass means the body of an animal that has been slaughtered for food, with the head, guts, part of the limbs and feathers or skin removed. The term meat yield, as used herein, means the amount of edible meat as a proportion of live body weight, or the amount of a specified meat cut as a proportion of live body weight. Weight gain
[000360] The present invention additionally provides a method for increasing weight gain in an individual, for example, poultry or pigs, which comprises giving said individual a feed comprising a feed additive composition according to present invention.
[000361] An "increased weight gain" refers to an animal that has increased body weight when fed with the feed that comprises a feed additive composition compared to an animal that is fed a feed without said feed composition. feed additive. Necrotic enteritis
[000362] Necrotic enteritis is an acute or chronic enterotoxemia seen in chickens, turkeys and ducks worldwide, caused by Clostridium perfringens. Necrotic enteritis is often characterized by fibrino-necrotic enteritis, usually of the small intestine. Mortality can be from 5 to 50%, generally around 10%. The infection occurs through fecal-oral transmission. The spores of the causative organism are highly resistant. Predisposing factors include coccidiosis / coccidiasis, diet (high protein content), in ducks, possibly heavy strain, high viscosity diets (often associated with large inclusions of rye and wheat in the diet), feed and / or contaminated water, other debilitating diseases.
[000363] The present invention relates to increasing the individual's resistance to necrotic enteritis. In other words, the present invention is concerned with preventing or reducing the negative effect of necrotic enteritis.
[000364] The term "resistance to", as used here, can encompass the term "tolerance to". Therefore, in one embodiment, the individual may not be resistant to necrotic enteritis, but the individual may be able to tolerate necrotic enteritis, that is, without the negative effects on the individual's performance.
[000365] In one embodiment, the present invention relates to a feed additive composition according to the present invention for treating or preventing necrotic enteritis in an individual. Typically, the individual will be one who has been or will be stimulated with the species Clostridium perfringens and / or Eimeria. Such a stimulus may come from the environment or from the application of live microorganisms in the feed or drinking water, for example, when live coccid vaccines are used.
[000366] In another embodiment, the present invention relates to a feed additive composition for preventing and / or treating coccidiosis and / or necrotic enteritis in an individual.
[000367] The present invention further provides a method for preventing and / or treating necrotic enteritis and / or coccidiosis wherein an effective amount of a feed additive composition according to the present invention is administered to an individual. Immune response
[000368] Immune response, as used here, means one of the many ways in which DFMs modulate the immune system of animals, including increased antibody production, positive regulation of cell-mediated immunity, positive regulation of pro-inflammatory cytokines, and increased signaling of the Toll-type receptor. It is understood that immune stimulation of the gastrointestinal tract by DFMs can be advantageous in protecting the host against disease, and that immune suppression of the gastrointestinal tract can be advantageous for the host because less nutrients and energy are used to support immune function.
[000369] Preferably, the immune response is a cellular immune response.
[000370] Preferably, the immune response is measured by looking at the immune markers. Pathogenic bacteria
[000371] The term pathogenic bacteria, as used here, means, for example, toxigenic clostridial species, for example, Clostridium perfringens and / or E. coli and / or Salmonella spp and / or Campylobacter spp. In one embodiment, pathogenic bacteria can be pathogenic E. coli species for birds.
[000372] The present invention can reduce populations of pathogenic bacteria in an individual's gastrointestinal tract. Excretion of nutrients
[000373] In one embodiment, the present invention relates to reducing the excretion of nutrients in manure. This has positive effects on reducing environmental risks. For example, in a preferred embodiment, the present invention refers to the reduction of the nitrogen and / or phosphorus content in the manure of the individual. This therefore reduces the amount of nitrogen and / or phosphorus in the environment, which can be beneficial. Probiotics
[000374] For some applications, it is believed that DFM in the composition of the present invention can exert a probiotic culture effect. It is also within the scope of the present invention to add more probiotics and / or prebiotics to the composition of the present invention.
[000375] Here, a prebiotic is: "a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and / or activity of one or a limited number of beneficial bacteria".
[000376] The term "probiotic culture", as used here, defines live microorganisms (including bacteria or yeasts, for example) which, for example, when ingested or applied locally in sufficient quantities, beneficially affects the host organism, ie , for conferring one or more demonstrable health benefits to the host organism. Probiotics can optimize microbial balance on one or more mucous surfaces. For example, the mucosal surface may be the intestine, the urinary tract, the respiratory tract or the skin. The term "probiotic", as used here, also encompasses living microorganisms that can stimulate the beneficial ramifications of the immune system and at the same time reduce inflammatory reactions on a mucous surface, for example, the gastrointestinal tract.
[000377] Although there are no lower or upper limits for probiotic intake, it has been suggested that at least 106-1012, preferably at least 1O6-1O10, preferably 108-109, UFC as a daily dose will be effective to achieve beneficial health effects on an individual. Isolated
[000378] In one aspect, suitably, the enzyme or DFM used in the present invention can be in an isolated form. The term "isolated" means that the enzyme or DFM is at least substantially free of at least one other component with which the enzyme or DFM is naturally associated in nature and, as found in nature. The enzyme or DFM of the present invention can be provided in a form that is substantially free of one or more contaminants with which the substance could otherwise be associated. In this way, for example, it can be substantially free of one or more polypeptides and / or potentially contaminating nucleic acid molecules. Purified
[000379] In one aspect, preferably, the enzyme and / or DFM according to the present invention is in a purified form. The term "purified" means that the enzyme and / or DFM is present at a high level. The enzyme and / or DFM is desirably the predominant component present in a composition. Preferably, it is present at a content of at least about 90%, or at least about 95% or at least about 98%, said level being determined based on dry weight / dry weight with respect to the total composition being considered.
[000380] It is contemplated within the scope of the present invention that the modalities of the invention can be combined so that combinations of any of the elements described herein are included within the scope of the present invention. In particular, it is contemplated within the scope of the present invention that any of the therapeutic effects of bacteria can be exhibited concurrently. Nucleotide sequence
[000381] The scope of the present invention encompasses nucleotide sequences that encode proteins that have the specific properties defined herein.
[000382] The term "nucleotide sequence", as used here, refers to an oligonucleotide sequence or poly-nucleotide sequence, and variants, homologues, fragments and derivatives of these substances (as their portions). The nucleotide sequence can be of genomic, synthetic or recombinant origin, which can be double-stranded or single-stranded, representing the sense or antisense strand.
[000383] The term "nucleotide sequence" in connection with the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably, it means DNA, more preferably, the cDNA sequence encoding the present invention.
[000384] In a preferred embodiment, the nucleotide sequence, when referring to and when covered by the scope of the present invention, does not include the native nucleotide sequence according to the present invention when in its natural environment and when it is linked its associated sequence (s) ^) which is also / are in their natural environment. For ease of reference, we should call this preferred modality "non-native nucleotide sequence". In this sense, the term "native nucleotide sequence" means an entire nucleotide sequence that is in its native environment and when operationally linked to an entire promoter with which it is naturally associated, whose promoter is also in its native environment. However, the amino acid sequence within the scope of the present invention can be isolated and / or purified after the expression of a nucleotide sequence in its native organism. Preferably, however, the amino acid sequence within the scope of the present invention can be expressed by a nucleotide sequence in its native organism, but the nucleotide sequence is not under the control of the promoter with which it is naturally associated within. that organism.
[000385] Typically, the nucleotide sequence within the scope of the present invention is prepared using recombinant DNA techniques (i.e., recombinant DNA). However, in an alternative embodiment of the invention, the nucleotide sequence could be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers MH et al., (1980) Nuc Acids Res Symp Ser 215-23 and Horn T et al., (1980) Nuc Acids Res Symp Ser 225-232). Preparation of the nucleotide sequence
[000386] A nucleotide sequence encoding any protein that has the specific properties defined herein or a protein that is suitable for modification can be identified and / or isolated and / or purified from any cell or organism that produces said protein. Various methods are well known in the art for the identification and / or isolation and / or purification of nucleotide sequences. For example, PCR amplification techniques to prepare more than one sequence can be used once a suitable sequence has been identified and / or isolated and / or purified.
[000387] As an additional example, a library of genomic DNA and / or cDNA can be built using chromosomal DNA or messenger RNA from the organism that produces the enzyme. If the amino acid sequence of the enzyme is known, labeled oligonucleotide probes can be synthesized and used to identify clones encoding enzymes from the genomic library prepared from the organism. Alternatively, a labeled oligonucleotide probe containing sequences homologous to another known enzyme gene could be used to identify clones encoding enzymes. In the last box, hybridization and washing conditions with less stringency are used.
[000388] Alternatively, enzyme-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming bacteria negative for the enzyme with the resulting genomic DNA library, and then plating the transformed bacteria on agar plates containing a substrate for the enzyme (ie maltose) thus allowing clones to express the enzyme to be identified.
[000389] In a still further alternative, the nucleotide sequence encoding the enzyme can be prepared synthetically by established standard methods, for example, the phosphoramide method described by Beucage SL et al., (1981) Tetrahedron Letters 22, p 1859-1869, or the method described by Matthes et al., (1984) EMBO J. 3, p 801-805. In the phosphoramidite method, oligonucleotides are synthesized, for example, in an automatic DNA synthesizer, purified, ringed, linked and cloned into suitable vectors.
[000390] The nucleotide sequence can be of mixed genomic and synthetic origin, synthetic and mixed cDNA origin, or of genomic and mixed cDNA origin, prepared by linking fragments of synthetic, genomic or cDNA origin (as appropriate) ) according to standard techniques. Each linked fragment corresponds to several parts of the entire nucleotide sequence. The DNA sequence can also be prepared by polymerase chain reaction (PCR) system using specific primers, for example, as described in US 4,683,202 or in Saiki RK et al., (Science (1988) 239, pp 487-491). Amino acid sequences
[000391] The scope of the present invention also encompasses amino acid sequences of enzymes that have the specific properties defined herein.
[000392] For use in the present invention, the term "amino acid sequence" is synonymous with "polypeptide" and / or the term "protein". In some cases, the term "amino acid sequence" is synonymous with the term "peptide"; in some cases, the term "amino acid sequence" is synonymous with the term "enzyme".
[000393] The amino acid sequence can be prepared / isolated from a suitable source, or it can be produced synthetically or it can be prepared using recombinant DNA techniques.
[000394] The protein covered in the present invention can be used in conjunction with other proteins, particularly enzymes. Accordingly, the present invention also encompasses a combination of proteins, the combination comprising the protein / enzyme of the present invention and another protein / enzyme, which may be another protein / enzyme according to the present invention.
[000395] Preferably, the amino acid sequence, when related to and when covered by the scope of the present invention, is not a native enzyme. In this sense, the term "native enzyme" means an entire enzyme that is in its native environment and when it was expressed by its native nucleotide sequence. Sequence identity or sequence homology
[000396] The present invention also encompasses the use of sequences that have a degree of sequence identity or sequence homology with amino acid sequences of a polypeptide that has the specific properties defined herein or of any nucleotide sequence encoding that polypeptide (later in this document called "homologous sequence (s)"). Here, the term "homologous" means an entity that has a certain homology to the amino acid sequences in question and to the nucleotide sequences in question. Here, the term "homology" can be equated with "identity".
[000397] The amino acid sequence and / or homologous nucleotide sequence must provide and / or encode a polypeptide that retains functional activity and / or enhances the activity of the enzyme.
[000398] In the present context, a homologous sequence is understood to include an amino acid sequence that can be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the sequence in question. Typically, homologues will comprise the same active sites as the amino acid sequence in question. Although homology can also be considered in terms of similarity (i.e., amino acid residues that have similar chemical properties / functions), in the context of the present invention it is preferable to express homology in terms of sequence identity.
[000399] In the present context, a homologous sequence is understood to include a nucleotide sequence that can be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to a nucleotide sequence that encodes a polypeptide of the present invention (the sequence in question). Typically, homologues will comprise the same sequences that encode active sites, etc. than the sequence in question. Although homology can also be considered in terms of similarity (i.e., amino acid residues that have similar chemical properties / functions), in the context of the present invention it is preferable to express homology in terms of sequence identity.
[000400] Homology comparisons can be conducted by visual inspection, or more generally, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate% homology between two or more sequences.
[000401]% homology can be calculated over contiguous sequences, that is, one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called "ungapped" alignment. Typically, such alignments without gaps are made only on a relatively small number of residues.
[000402] Although this is a very simple and consistent method, it fails to take into account that, for example, in a pair of otherwise identical sequences, an insertion or deletion will cause the following amino acid residues to be placed out of alignment in this way, potentially resulting in a large reduction in% homology when a global alignment is made. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into account possible insertions and deletions without unduly penalizing the degree of total homology. This is achieved by inserting "gaps" in the sequence alignment to try to optimize local homology.
[000403] However, these more complex methods designate "gap gaps" for each gap that occurs in the alignment so that, for the same number of identical amino acids, an alignment of sequences with the fewest possible gaps - reflecting a greater relationship between the two sequences compared - will reach a degree greater than one with many gaps. "Related gap costs" are typically used, which place a relatively high cost for the existence of a gap and a minor penalty for each subsequent waste in the gap. This is the most commonly used gap scoring system. High gap penalties will logically produce optimized alignments with fewer gaps. Most alignment programs allow gap penalties to be modified. However, it is preferable to use the default values when using such a program for comparisons between sequences.
[000404] The calculation of the% of maximum homology, therefore, first requires the production of an optimal alignment, taking into account the penalties for a gap. A suitable computer program to perform such an alignment is Vector NTI (Invitrogen Corp.). Examples of programs that can make comparisons between sequences include, but are not limited to, the BLAST package (see Ausubel et al 1999 Short Protocols in Molecular Biology, 4th Ed - chapter 18), BLAST 2 (see FEMS Microbiol Lett 1999 174 (2 ): 247-50; FEMS Microbiol Lett 1999 177 (1): 187-8 and tatiana@ncbi.nlm.nih.qov), FASTA (Altschul et al 1990 J. Mol. Biol. 403-410) and AlignX, by example. At least BLAST, BLAST 2 and FASTA are available for offline and online search (see Ausubel et al 1999, pages 7-58 to 7-60).
[000405] Although the% final homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used, which assigns scores for each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a commonly used matrix is the BLOSUM62 matrix - the standard matrix for the BLAST program package. Vector NTI programs generally use public default values or a custom symbol comparison table, if provided (see user manual for additional details). For some applications, it is preferable to use the default values for the Vector NTI package.
[000406] Alternatively, the percentage of homology can be calculated using the multiple alignment component in Vector NTI (Invitrogen Corp.), based on an algorithm analogous to CLUS-TAL (Higgins DG & Sharp PM (1988), Gene 73 ( 1), 237-244).
[000407] When the program has produced an optimal alignment, it is possible to calculate the% homology, preferably the% sequence identity. The program typically does this as part of the sequence comparison and generates a numerical result.
[000408] If gap penalties are used when terminating the sequence identity, then preferably the following parameters are used for aligning sequence pairs:

[000409] In one embodiment, CLUSTAL can be used with the gap penalty and gap length adjusted as defined above.
[000410] Suitably, the degree of identity with respect to a nucleotide sequence is determined over at least 20 contiguous nucleotides, preferably over at least 30 contiguous nucleotides, preferably over at least 40 contiguous nucleotides preferably over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 100 contiguous nucleotides.
[000411] Suitably, the degree of identity with respect to a nucleotide sequence can be determined throughout the sequence. Hybridization
[000412] The present invention also encompasses sequences that are complementary to the nucleic acid sequences of the present invention or sequences that are capable of hybridizing to the sequences of the present invention or to sequences that are complementary thereto.
[000413] The term "hybridization" as used here, should include "the process by which a nucleic acid strand joins with a complementary strand through base pairing" as well as the amplification process, as performed in the system technology polymerase chain reaction (PCR).
[000414] The present invention also encompasses the use of nucleotide sequences that are capable of hybridizing to sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof.
[000415] The term "variant" also encompasses sequences that are complementary to the sequences that are capable of hybridizing to the nucleotide sequences presented here.
[000416] Preferably, complementary sequences are those capable of hybridizing under stringent conditions (eg 50 ° C and 0.2xSSC {1xSSC = NaCl 0.15 M, Na3 citrate 0.015 M pH 7.0}) to sequences of nucleotides presented here.
[000417] Most preferably, complementary strings are those that are able to hybridize under high stringency conditions (eg 65 ° C and 0.1xSSC {1xSSC = 0.15 M NaCI, 0.015 M Naitrate pH 7.0 }) to the nucleotide sequences presented here.
[000418] In a more preferred aspect, the present invention comprises nucleotide sequences that can hybridize to the nucleotide sequence of the present invention, or to its complement, under highly stringent conditions (for example, 65 ° C and 0.1xSSC). Examples Example 1 Materials and methods
[000419] Three thousand six hundred day old male Cobb chicks were purchased from a commercial brooder. At the beginning of the study, fifty males were allocated to each treatment henhouse by blocks. The study consisted of the following treatments (Table 1):
1 E. coli phytase. 2 Bacillus licheniformis amylase, Trichoderma reesei xylanase, Bacillus subtilis protease. 3 Enviva Pro ® is a combination of Bacillus subtilis strains Bs2084, LSSAO1 and 15AP4, supplied by Danisco A / S. 93/129 5 4 Axtra XAP ® supplied by Danisco A / S. Petition 870200053635, of 04/30/2020, p. 97/145
[000420] The weights of birds per chicken coop were recorded at the beginning of the study, on days 23, 35 and at the end (day 42). The chicken coop was the unit of measurement. The diets of broilers were given as bran (initial) or pellets (growth and finishing). Diets meet or exceed NRC standards (Table 2). The mixer was discarded to avoid cross contamination of the diets. All treatment rations were mixed using a Davis S-20 mixer and pelleted using a California Pellet Mill (cold pellet temperature 65 to 70 C). Samples were collected from each treatment diet at the beginning, middle and end of each batch and mixed together to confirm the enzymatic activities and the presence of Enviva Pro in the feed.


[000421] The birds received adequate feed for the treatment from day 0 to 42. The enzymes and Enviva Pro were supplied by Danisco in mixtures and levels suitable for all experimental treatments. All diets contained 500 FTU of E. coli phytase in the background. The chicken coops were arranged inside the facility to avoid direct contact in order to avoid contamination. A change from the initial to the growth diet occurred on the 23rd. The growth diet was replaced by the termination diet on the 35th. At each feed change, the feeders were removed from the chicken houses by block, weighed again, emptied and filled again with the proper treatment diet. On the final day of the study, the ration was weighed. The chicken houses were checked daily for mortality. When a bird was selected for slaughter or found dead, the date and weight of removal (kg) were recorded. A gross necropsy was performed on all birds killed or selected for slaughter to determine sex and the probable cause of death. Signs of necrotic enteritis were observed.
[000422] All chicken houses had approximately 10.2 cm (4 inches) of bed constructed with a fresh pine sawdust coating.
[000423] All birds were vaccinated by spraying before being placed in chicken houses with a commercial coccidiosis vaccine (Coccivac-B). On days 20, 21 and 22 all birds, except treatment 1, were administered with a culture broth of C. per-fringens. A field isolate of C. perfringens known to cause NE and which originates from an operation with commercial broilers was used as the stimulating organism. The fresh inoculum was used every day. The titration levels were approximately 1.0 X 108-9. Each chicken coop received the same amount of inoculum. The inoculum was administered by mixing it in the ration found at the base of the feed tube. On day 23, five birds from each henhouse were selected, euthanized, weighed in groups, and examined for the degree of presence of necrotic enteritis lesions. The score was based on a score of 0 to 3, with 0 being normal and 3 being the most severe (0 = none, 1 = mild, 2 = moderate, 3 = severe / severe; Hofacre et al., 2003 J. Appl Plt Res. 12: 60-64). No concomitant pharmacological therapy was used during the study.
[000424] The averages were separated using paired t tests. Significant differences were considered to be P <0.05. The chicken coops were used as the experimental unit. Results
[000425] Figure 1 shows the necrotic enteritis lesion scores in broilers in a necrotic enteritis stimulus model based on a 0 to 3 score system. SEM grouped = 0.15
[000426] Stimulated control treatment increased injury scores compared to unstimulated control treatment. The addition of DFMs with a combination of xylanase, amylase, pro-tease and phytase reduced lesion scores compared to all other treatments. The addition of DFMs in combination with the enzymes reduced lesion scores compared to DFMs alone or enzymes alone.
[000427] Figure 2 shows the body weight gain of broilers in a necrotic enteritis stimulation model. Standard deviation of the mean (SEM) grouped = 28.6
[000428] Figure 2 shows that a combination of DMF (Enviva Pro®) with a combination of xylanase, amylase, protease and phytase significantly improved body weight gain (PC gain) in broilers stimulated with Clostridium perfringens compared to the stimulated control - even if it results in an improved PC gain over a negative control (that is, an unstimulated control). This was significantly better than any other treatment.
[000429] Figure 3 shows the ratio of feed conversion of broilers in a necrotic enteritis stimulus model. Standard deviation of the mean (SEM) grouped = 0.016
[000430] The combination of Enviva Pro (DFM) with a xylanase, amylase, protease and phytase significantly improved (reduced) FCR (g of PC gain / g of feed intake) of broilers from birth to 42 days in compared to stimulated control, and to enzymes alone and other treatments. Example 2. Materials and methods
[000431] 500 male Cobb broiler chicks were obtained from a commercial brooder. A total of 26 chicks were randomly assigned to one of 8 breeding hens per treatment. Floor chicken coops (1.5 m2 / chicken coop (16 ft2 / chicken coop)) were located in a housing with side curtains containing controlled heating, circulation fans, heat lamps and fresh wood sawdust. The birds were exposed to fluorescent light in a 24-hour light cycle for the first four days and then a 16-hour light cycle: 8 hours of darkness for the remainder of the experiment. The ration was supplied in bell feeders and the water was supplied at will through drinkers with spouts. A 5X dose of Coccivac-B (Intervet) was administered manually with a syringe into the oral cavity of the day old chicks. Table 3, Experimental design of example 2.
1 E. coli phytase. 2 Bacillus amylollquefaciens amylase, Trichoderma reesei xylanase, Bacillus subtilis protease. 3 Enviva Pro ® is a combination of Bacillus subtilis strains Bs2084, LSSAO1 and 15AP4, supplied by Danisco A / S. 4 Avizyme 1505 ® supplied by Danisco A / S. 98/129 Petition 870200053635, of 4/30/2020, p. 102/145
[000432] The chicks were administered diets with or without Enviva Pro or xylanase, amylase, and protease (Avizyme 1502; Table 3). Enzymes and Enviva Pro were supplied by Danisco in mixtures and levels suitable for all experimental treatments. All diets contained 500 FTU of E. coli phytase. The chicken coops were arranged inside the facility to avoid direct contact in order to avoid contamination.
[000433] All diets were diets based on corn-soybean meal-DDGS. The initial diets were provided during the study (d 1-20). The diets were pelleted (65 to 70 ° C) and crumbled. Samples were collected from each treatment diet at the beginning, middle and end of each batch and mixed together to confirm the enzymatic activities and the presence of Enviva Pro in the feed. Table 4. Composition of the experimental diet in example 2.


[000434] Body weights and weights of feeders were recorded on days 1, 11, 20, 38 and 48 to calculate feed intake, body weight gain and feed conversion. Mortality and slaughter selections were monitored daily and used to adjust feed intake and gain. A bird of six chicken houses for breeding was euthanized by cervical dislocation to collect mucous scrapes on days 11 and 20. Mucous scrapes were collected from the ileum (Meckel's diverticulum to the ileocecal junction). The ileum was removed and cut along its length to expose the lumen, and then washed quickly and gently with PBS to remove digestion material. The edge of a microscope slide was used to remove the mucous layer by scraping along the length of the cut tissue section. The mucous layer was immediately fixed by freezing between aluminum plates in liquid N to preserve the integrity of the RNA and was stored in individual "whirl-pack" bags. Frozen tissue samples were stored in liquid N during sampling and at -80 C before analysis. The total RNA of the mucosal scraping was isolated using the Trizol reagent (Invitrogen) using a mechanical homogenizer for tissue disruption. The total RNA (0.5 pg) was reverse transcribed in complementary DNA using iScript (Bio-Rad) according to the manufacturer's recommendations. The amount of mRNA from the secreted inflammatory cytokine genes (interleukin-10, interferon-y and interleukin-17) was assessed using specific primers for chickens. Additionally, the amount of TATA-BP, HPRT-1 and β-actin mRNA was measured for data normalization using the ge-Norm software. The number of times of change in the amount of mRNA in gene expression was determined using the modified Ct delta-delta equation, as described by Rudrappa and Humphrey (2007) J. Nutr. 137: 427-432 and transformed into a log for data analysis.
[000435] The averages were separated using paired t tests. Significant differences were considered to be P <0.05. The birds were used as the experimental unit for mRNA data. Results
[000436] Figure 4 shows the amount of mRNA of the interferon-gamma gene in the mucous scraps of broiler ileum. Age 11 days: Standard deviation of the grouped mean = 0.1 Age 20 days Standard deviation of the grouped mean = 0.6
[000437] The combination of Enviva Pro and xylanase, amylase, protease + phytase positively regulated the expression of IFR-g in the ileum of 11-day-old broilers that received a live anti-coccidiosis vaccine live in the hatch compared to the negative control, Enviva Pro + phytase, and xylanase, amylase, protease + phytase. On day 21, Enviva Pro + phytase, and the combination of Enviva Pro and xylanase, amylase, protease + phytase negatively regulated the expression of IFR-g in the ileum compared to the negative control. These data suggest that modulation of the immune response may be one of the improved performance mechanisms of DFMs in combination with the 4 enzymes in broilers.
[000438] Figure 15 shows the feed conversion ratio of broilers at day 48 of age. Age 48 days: Standard deviation of the grouped mean = 0.041 Example 3 Materials and methods
[000439] A digestibility test with broilers was conducted to determine the effects of dietary enzymes and treatments with DFMs on the use of nutrients. The cages were housed in rooms with a controlled environment. The birds received 20 hours of fluorescent lighting and were left with free access to diets and water. On day 1, a live vaccine for broiler coccidiosis was given to all chicks via drinking water. Paper was placed on the wire floor of the cage for the first three days to allow recycling of Eimeria's oocysts. The study consisted of the following treatments (Table 5): Table 5. Experimental design of example 3.
1 E. coli phytase. 2 Bacillus amyloliquefaciens amylase 1, Bacillus li-cheniformis amylase 2, Trichoderma reesei xylanase, Bacillus subtilis protease. 3 Enviva Pro ® is a combination of Bacillus subtilis strains Bs2084, LSSAO1 and 15AP4, supplied by Danisco A / S. 4 Avizyme 1505 ® supplied by Danisco A / S. 5 Axtra XAP ® supplied by Danisco A / S.
[000440] 192 birds were weighed individually and distributed, based on body weight, to 48 cages (4 birds / cage). The 8 diet treatments were then randomly assigned to six cages each. The birds received adequate initial feed for the treatment from 0 to 21 days. Enzymes and Enviva Pro were supplied by Danisco in mixtures and levels suitable for all experimental treatments. All diets contained 500 FTU of E. coli phytase. The chicken coops were arranged inside the facility to avoid direct contact in order to avoid contamination. The birds were fed with the initial diets (Table 6) in the form of puree throughout the experiment. Table 6. Composition of the experimental diet in example 3.


[000441] On day 21, four birds per cage were euthanized by intracardiac injection of sodium pentobarbitone and the contents of the lower ileum were expressed by gentle washing with distilled water The digestion materials of the birds inside a cage were grouped, resulting in six samples by diet treatment. The samples of the digestion material were frozen immediately after collection, lyophilized and processed. Samples of digestion material and diets were analyzed for Ti, DM, GE, starch, fat, N and amino acids, excluding tryptophan, according to standard procedures. The calculation of the ileum digestibility coefficients was performed as reported by Ravindran et al. (2005), based on the concentration of indigestible Ti. The energy contribution of starch, fat and protein to the digestible energy of the ileum was calculated based on the average gross energy of the starch (4.2 kcal / g), fat (9.4 kcal / g), or protein (5, 5 kcal / kg). The improvement of digestible amino acids in response to enzymes and DFMs was expressed in relation to the amount of undigested amino acids at the ileum level; the slope of that linear function was used as an indicator of the effects of additives on amino acid digestibility.
[000442] The averages were separated using paired t tests. Significant differences were considered to be P <0.05. The cages were used as the experimental unit. Results
[000443] Figure 5 shows the apparent digestible energy of broiler ileum at 21 days of age. Standard deviation of the grouped mean = 0.027
[000444] The addition of Enviva Pro (a DFM) in combination with an amylase, xylanase, protease and phytase showed commercially relevant increases in the digestible energy of the ileum compared to the enzymes alone and with the negative controls. These data indicate that DFMs improved the effects of these exogenous enzymes on the energy digestibility of poultry diets. For clarity, Amylase 2 is through the use of amylase in AxtraXAP and Amylase 1 is through the use of amylase in Avizyme 1502.
[000445] Figure 6 shows the increases in ileum amino acid digestibility for three dietary treatments as a function of the control treatment as a function of the ile's undigested amino acids in the control treatment using 21-day-old broilers.
[000446] The Figure shows the improvement in the digestion of amino acids in the ileum of dietary treatments in relation to the undigested fraction of amino acids in the ileum of broilers in the control treatment. Each point within a treatment represents one of the measured amino acids. The addition of Enviva Pro over xylanase, amylase 2, protease + phytase increased the digestibility of the amino acid ileus (+ 11.3%) compared to Enviva Pro + phytase (+ 3.6%) and xylanase, amylase 2, protease + phytase alone (ie without DFM) (+ 4.7%). These data indicate that DFMs have improved the effectiveness of these exogenous enzymes in increasing the digestibility of amino acids in poultry diets.
[000447] Figure 7 shows the improvement of the digestible energy of the ileum in relation to the control treatment using broilers with 21 days of age.
[000448] The Figure shows the increase in the digestible energy of the ileum of each dietary treatment in comparison to the negative control treatment with phytase. In addition, the calculated contributions of energy from starch, fat or protein are presented. The addition of Enviva Pro in combination with xylanase, amylase 2, protease + phytase increased the digestible energy of the ileum compared to treatment with Enviva Pro + phytase and treatment with xylanase, amylase 2, protease + phytase alone. The addition of Enviva Pro in combination with xylanase, amylase 1, protease + phytase produced commercially important increases in the digestible energy of the ileum compared to the enzymes alone. These data indicate an improved ability of the 4 enzymes to increase the digestible energy of the ileum of the broiler diets in the presence of DFMs. Example 4 Materials and methods
[000449] A digestibility test with broilers was conducted to determine the effects of dietary enzymes and treatments with DFMs on the use of nutrients. The cages were housed in rooms with a controlled environment. The birds received 20 hours of fluorescent lighting and were left with free access to diets and water. On day 1, a live vaccine for broiler coccidiosis was given to all chicks via drinking water. Paper was placed on the wire floor of the cage for the first three days to allow recycling of Eimeria's oocysts. The study consisted of the following treatments (Table 7): Table 7. Experimental design of example 4.

1 E. coli phytase. 2 Bacillus amyloliquefaciens amylase 1, Bacillus li-cheniformis amylase 2, Trichoderma reesei xylanase, Bacillus subtilis protease. 3 Enviva Pro ® is a combination of Bacillus subtilis strains Bs2084, LSSAO1 and 15AP4, supplied by Danisco A / S. 4 Avizyme 1505 ® supplied by Danisco A / S. 5 Axtra XAP ® supplied by Danisco A / S.
[000450] 144 birds were weighed individually and distributed, based on body weight, to 36 cages (4 birds / cage). The 6 diet treatments were then randomly assigned to six cages each. The birds received adequate initial feed for the treatment from 0 to 21 days. Enzymes and Enviva Pro were supplied by Danisco in mixtures and levels suitable for all experimental treatments. The chicken coops were arranged inside the facility to avoid direct contact in order to avoid contamination. The birds were fed with the initial diets (Table 6) in the form of puree throughout the experiment. Table 8. Composition of the experimental diet of example 4 ^


[000451] Feed intake and total excreta production were measured quantitatively per cage over four consecutive days (from the 17th to the 20th) for the determination of the apparent metabolizable energy corrected for nitrogen (AMEn) and retention nitrogen. Daily excreta collections were grouped inside a cage, mixed in a mixer and subsampled. Each subsample was lyophilized, ground to pass through a 0.5 mm sieve and stored in air-tight plastic containers at - 4 C until analysis. The processed samples were analyzed for DM, GE and N using standard procedures.
[000452] The averages were separated using paired t tests. Significant differences were considered to be P <0.05. The cages were used as the experimental unit. Results
[000453] Figure 8 shows the apparent metabolizable energy corrected for nitrogen AMEn from dietary treatments given to broilers with 17 to 21 days of age. Standard deviation of the grouped mean = 0.015
[000454] The addition of Enviva Pro in combinations with xylanase, amylase, protease + phytase increased the AMEn of the diets in response to enzymes compared to the negative control diet. In particular, the addition of Enviva Pro in combination with xylanase, amylase 2, protease + phytase increased the AMEn of diets in response to enzymes compared to diets with Enviva Pro alone.
[000455] Figure 9 shows the nitrogen retention of broilers with 17 to 21 days of age. Standard deviation of the grouped mean = 0.006
[000456] The addition of Enviva Pro in combination with xylanase, amylase, protease + phytase increased the nitrogen retention of broilers in response to enzymes compared to the negative control diet. In particular, the addition of Enviva Pro over xylanase, amylase 2, protease + phytase increased the nitrogen retention of broilers in response to enzymes compared to broilers fed Enviva Pro only diets. Example 5 Materials and methods
[000457] 308 male Ross broiler chicks were obtained from a commercial brooder. A total of 10 chicks were randomly assigned to one of 6 replicate cages per treatment. The birds were exposed to fluorescent light in a 24-hour light cycle for the first four days and then a 16-hour light cycle: 8 hours of darkness for the remainder of the experiment. Food and water were supplied at will. The experimental design consisted of the following treatments.
1 E. coli phytase. 2 Bacillus amyloliquefaciens amylase, Trichoderma reesei xylanase, Bacillus subtilis protease. 2 Enviva Pro ® is a combination of Bacillus subtilis strains Bs2084, LSSAO1 and 15AP4, supplied by Danisco A / S. 4 Avizyme 1505 ® supplied by Danisco A / S. 111/129 Petition 870200053635, of 4/30/2020, p. 115/145
[000458] In treatments 2 to 6, a vaccine for overdosed coccidiosis (recommended dose x5) (B, Intervet) was administered manually with a syringe in the oral cavity of day old chicks. In treatment 2, salinomycin (Bio-cox) was used at the approved level (60 g / MT) as a coccidiostatic. The chicken coops were arranged inside the facility to avoid direct contact in order to avoid cross contamination with Eimeria oocysts and DFMs. The enzymes and Enviva Pro were supplied by Danisco A / S in mixtures and levels suitable for all experimental treatments. All diets contained 500 FTU of E. coli phytase in the background. Table 10. Composition of the experimental diet in example 5.

[000459] 2 birds per replicated cage were euthanized at 14 days of age to collect mucous scrapes from the middle ileum. The oils were washed with a stream of distilled water and opened by cutting with a pair of scissors. The open sections were laid flat on a clean glass plate. The mucosa was carefully scraped from the middle region of the ileum with the long edge of a glass slide. Each sample was stored in 2 ml of RNAIater (Ambion) and frozen in a -80 C freezer. The samples were thawed on ice. The total RNA was isolated with Trizol reagent according to standard protocols. RNA integrity was determined on an agarose gel. The RNA was reverse transcribed with MMLV reverse transcriptase. Mucin expression (MUC2) was determined by real-time PCR on a real-time MylQ equipment from Bio-rad.
[000460] The averages were separated using paired t tests. Significant differences were considered to be P <0.05. The birds were used as the experimental unit for mRNA data. Results
[000461] Figure 10 shows the amount of mRNA of the MUC2 gene in the mucous scraps of the 14-day-old broiler ileum. Standard deviation of the grouped mean = 0.14
[000462] The addition of Enviva Pro in combination with xylanase, amylase, protease + phytase negatively regulated the expression of MUC 2 in the ileum of chickens stimulated with a 5 X dose of a live coccidiosis vaccine compared to the stimulated control. These data suggest that a reduction in the loss of endogenous amino acids caused by reduced mucin secretion may be responsible for the improved performance of broilers that receive combinations of DFMs and the 4 enzymes. Example 6 Materials and methods
[000463] Tissue samples were taken from broiler chicks in the test presented in example 1 at 23 days of age. The treatment specifications are shown in Table 1. The jejunum, pancreas and liver were removed from 2 birds from each chicken coop and the grouped mucosa resulting in eight samples per treatment. The samples were rinsed in buffer solution (PBS) immersed in a tissue storage reagent (RNAIater) according to the manufacturer's protocol and stored at -80 ° C. Total RNA was isolated from each tissue sample using a one-step phenol-chloroform extraction method, as described by Chozzynski and Saachi (1987; Anal. Biochem. 162: 156-9). The RNA concentration was determined by measuring the absorbance at 260 nm (Nanodrop) and the integrity was monitored by gel electrophoresis in 1.2% agarose gels. Only RNA with sufficient purity and having an absorption ratio at 260 nm to 280 nm greater than 1.87 were considered for use.
[000464] The microarrays were manufactured using 70 base pair oligonucleotides (Opereon Biotechnologies Inc) according to the protocol described by Druyan et al. (2008; Poult. Sci. 87: 2418-29). The experimental design of the arrangement was a complete interlaced loop design, as described by Garosi et al. (2005; Br. J. Nutr. 93: 425-32) in which each sample is compared directly with the others in multiple pairs, allowing all treatments to be compared. The samples were marked according to the method described by Druyan et al. (2008; Poult. Sci. 87: 2418-29) in which half of the samples would be labeled with Cy3 and half with Cy5, which are fluorescent cyanine dyes. Hybridization was performed using the Pronto Plus microarray hybridization kit! before the addition of cDNA probes labeled with Cy3 and Cy5 and the samples were covered with a transparent glass coverslip (Lifterslip) and allowed to hybridize for 16 hours. The microarrays were then digitized on a Scan Array Gx PLUS microarray digitizer adjusted to a 65% laser energy to acquire the images.
[000465] The total RNA of the individual samples was reverse transcribed to produce cDNA which was then used as a template for the qPCR amplifications, as described by Druyan et al. (2008; Poult. Sci. 87: 2418-29). The thermocycling parameters were optimized for each gene and each gene was amplified independently in duplicate within a single pass of the instrument.
[000466] The data files were generated from the digitalized images of the microarrays, but extracting the raw intensity data for each slide and the combination of dyes using the ScanAlyze Software. The intensity data files were then analyzed using JMP Genomics which includes an initial Iog2 transformation. Normalization of the data was done using locally weighted regression and smoothing first within the array and across all the arrangements. The resulting normalized Iog2 intensities were analyzed using a mixed ANOVA model.
[000467] The average intensities were compared using a significance limit based on the Bongerroni correction of P = 0.05. For the complete array, including all replicates, an average intensity per grid was calculated for each gene using the 3 probes side by side, resulting in a total of four replicated averages, one from each grid, per gene. The data for the Ct ratio of the duplicate samples (Ct of the sample gene: Ct of the sample GAPDH) depending on the treatment were subjected to unidirectional ANOVA. Results
[000468] Expression data was collected using the microarray platform and a "heat map" was produced to view data for the jejunum (Figure 16) and pancreas (Figure 17). The relative expression levels of six genes of interest have been converted into visual cues based on the scale seen in Figure 16. The least expressed genes are marked with a minus sign and highly expressed genes are marked with a plus sign ( "+"); while a higher gray intensity shows a greater difference in the average expression level of the treatments. The genes that were measured and their supposed functions, as seen in Table 11. Real-time PCR was used to validate the gene expression shown on the heat map for sucrase isomaltase (SI) and amylase 2A (AMY2a) and they were highly correlated to the arrangement data. Table 11. Supposed function of the measured genes.

[000469 Figure 16 shows a heat map of the expression profiles of the genes of interest for all treatments for the jejunum at 23 days of age.
[000470] Figure 17 shows a heat map of the chicken alpha amylase expression profile for all treatments in the pancreas at 23 days of age.
[000471] In Figures 16 and 17, the code is as follows: Control not stimulated = Control not stimulated + phytase CC = Control stimulated + phytase CC + Amylase = Control stimulated + phytase + amylase CC + XAP = Control stimulated + phytase + xylanase + amylase + protease CC + EP = Control stimulated + phytase + Enviva Pro CC + EP + Amylase = Control stimulated + phytase + amylase + Enviva Pro CC + EP + XAP = Control stimulated + phytase + xylanase + amylase + protease + Enviva Pro.
[000472] The expression of oligopeptide transporter 1 (PEPT1) has been increased by xylanase + amylase + protease + phytase, and has been further increased when in combination with Enviva Pro. PEPT1 is part of a peptide transport system and is responsible for absorption of a wide range of di- and tri-peptides.
[000473] Glycokinase (GCK) expression was downregulated by the stimulated control, but a combination of amylase + phytase or xylanase + amylase + protease + phytase with Enviva Pro produced a positive regulation similar to the unstimulated control. The extent of positive regulation was greater than when xylanase + amylase + protease + phytase were used with Enviva Pro.
[000474] A similar structure was also seen with isomaltase sucrase (SI), where the combination of Enviva Pro and amylase + phytase or xylanase + amylase + protease + phytase produced greater positive regulation than stimulated and unstimulated controls. GCK is a key enzyme in glucose metabolism and SI is responsible for the hydrolysis of sucrose and iso-maltose, and therefore has an important role in the digestion and absorption of carbohydrates in animals.
[000475] Occlusive junction protein 1 (ZO1) was the most highly expressed in the stimulated control. A reduction was seen with enzyme treatments, but greater negative regulation in expression was seen when Enviva Pro was used and so, particularly, when in combination with xylanase + amylase + protease + phytase, which produced a similar level of regulation negative than the unstimulated control. ZO1 is a protein that is on the cytoplasmic face of the occlusive junctions, there are several roles for this protein, ranging from signal transduction for the assembly of the occlusive junction to stability of the occlusive junctions themselves.
[000476] The CD3 T cell antigen (CD3D) was highly expressed in the stimulated control. The enzyme-only treatments reduced expression a little, but it was significantly down-regulated when in combination with Enviva Pro. The combination of xylanase + amylase + protease + phytase produced the highest down-regulation of enzyme treatments, and when in combination with Enviva Pro, produced an even greater negative regulation, close to that seen for unstimulated control. CD3D is a surface molecule found in T cells and plays an important role in signal transduction during coupling of the T cell receptor and is part of the T cell / CD3 receptor complex.
[000477] Alpha amylase (AMY2A) was highly expressed in unstimulated and stimulated controls, but the addition of amylase + phytase or xylanase + amylase + protease + phytase resulted in reduced expression, which was further reduced when Enviva Pro was used in combination, particularly for xylanase + amylase + protease + phytase. Chicken alpha amylase is produced mainly in the pancreas and plays an important role in the digestion of starch. Discussion
[000478] The increase in expression of the peptide transporter oligopeptide transporter 1 (PEPT1) when xylanase + amylase + pro-tease + phytase was given, particularly in combination with Enviva Pro, suggests an increased availability of the peptides and thus a greater need for peptide transporters, which indicates a synergistic effect of enzymes and DFMs to increase peptide adsorption for the animal, which allows for greater growth. The performance results of the animal of example 1 corroborate this conclusion. The increase in the expression of glucokinase and sucrase isomerase with the combination of amylase + phytase, or xylanase + amylase + protease + phytase, and Enviva Pro suggests that there was an increased absorption of glucose, and an increased availability of sucrose and isomaltose at the brush border , which indicates a positive interaction between the enzyme and DFMs to increase the absorption of carbohydrates in the small intestine and thus increase the availability of energy from the diet. The reduction in glucokinase expression for the stimulated control suggests that stimulation with Clostridium perfringens caused mucosal damage and that the addition of Enviva Pro and xylanase + amylase + protease + phytase alleviated this.
[000479] The effect of Enviva Pro in reducing the expression of occlusive junction protein 1 indicates less need for protein turnover in the intestine, which may be related to high intestinal integrity. The increased expression in the stimulated control, however, suggests that the protein degradation / need was high due to the failure of intestinal integrity, possibly due to infections by coccidia and Clostridium perfringens. The enzymes alone had some effect in improving this, but the additive effect seen with Enviva Pro suggests a greater benefit generated by the combination. This indicates that Enviva Pro acts by increasing intestinal integrity and, thus, benefits the animal's health. Increased intestinal integrity and thus absorption capacity may be one of the mechanisms by which the effectiveness of exogenous enzymes is increased when a DFM is present.
[000480] The increased expression of the CD3 T cell antigen in the stimulated control indicates increased cell-mediated immune response caused by the stimulus. In these conditions, birds will be subjected to underperforming performance because the immune response will require energy that could be used for growth, and because some birds will experience a response to systemic disease. The increased expression of this immune marker was strongly reversed when Enviva Pro was used alone or in combination with enzymes. The negative regulation of the immune response in the intestine may be one of the mechanisms by which the efficacy of exogenous enzymes in the absorption of nutrients and performance is increased when a DFM is present.
[000481] Negative regulation of alpha amylase (AMY2A) production that was seen with the combination of amylase + phytase, or xylanase + amylase + protease + phytase suggests that the chicken is reducing its production of endogenous amylase as a response to exogenous enzymes supplied. The additive effect seen with Enviva Pro and xylanase + amylase + protease + phytase suggests that DFM is working synergistically with exogenous enzymes to allow the bird to use the energy it would have spent producing enzymes for digesting starch in the diet.
[000482] The net effect of a negatively regulated immune response and greater intestinal integrity and better digestion and absorption of nutrients with the combination of enzymes and DFMs, clearly determines enhanced production performance of broilers. Example 7 Materials and methods
[000483] A digestibility test with broilers was conducted to determine the effects of dietary enzymes and treatments with DFM on energy use. 308 288-day-old male Ross chicks were obtained from a commercial brooder and hatched in chicken coops with barbed wire battery until the 14th. The birds were vaccinated with a live vaccine for brood coccidium (Coccivac-B) . The chicks were fed an initial corn-based diet-SBM-DDGS. The experimental diets were given to the chicks from the 14th to the 21st. Feed and water were provided at will throughout the 21-day period. Six chicks were housed by chicken coop in battery hens located inside a room with controlled environment, where they received supplemental heat starting at 35 ° C on the day of age and reducing by 2 ° C weekly. Light was provided at 23Light: 1 Dark. On day 15, the chicks were weighed individually, classified, the wings were tied and were randomly allocated to the experimental units using a completely randomized design. Each treatment consisted of 8 chicken houses per treatment. The study consisted of the following treatments (Table 12):
1 Buttiauxella phytase. 2 Bacillus licheniformis amylase, Trichoderma reesei xylanase, Bacillus subtilis protease. 3 Enviva Pro ® is a combination of Bacillus subtilis strains Bs2084, LSSAO1 and 15AP4, supplied by Danisco A / S. 4 GalliPro Tect is a DFM comprised of a strain of Bacillus licheniformis (DSM17236).
[000484] The enzymes and DFMs were supplied and supplied by Danisco in mixtures and levels suitable for all experimental treatments. The chicken coops were arranged inside the facility to avoid direct contact in order to avoid cross contamination. The birds were fed with the initial diets (Table 13) in puree form during the experimental period.

[000485] Clean droppings trays were put in place for the last 2 days and droppings samples were collected by chicken coop on day 21. The collected droppings samples were frozen at -20 ° C before being dried in an oven at 65 ° C for 3 days to determine the dry matter (AOAC International, 2005; method 934.01). The feed samples were also corrected for the dry matter base by measuring 5.0 g of each sample and drying them in an oven at 100 ° C for 24 h. The excrement samples were then crushed through a 1 mm mesh while the feed samples were crushed into a 0.5 mm mesh. Excrement samples and diets were analyzed for Ti, DM, GE, and N, according to standard procedures. The calculation of apparent metabolizable energy (AME) was based on the concentration of the indigestible marker (Ti) and the gross energy of the diets and excrement. Adequate corrections were made for differences in moisture content. N-corrected AME (AMEn) was determined to retain zero nitrogen by multiplying by 8.22 kcal per gram of nitrogen retained in the body (Hill and Anderson, 1958; J. Nutr. 64: 587-603).
[000486] The averages were separated using paired t tests. Significant differences were considered to be P <0.05. The cages were used as the experimental unit. Results
[000487] Figure 18 shows the apparent metabolizable energy corrected by the nitrogen retention (AMEn) of broilers with 21 days of age. DFM effect; P <0.001; Enzyme effect; P <0.001; DFM x Enzyme effect; P = 0.27; Standard deviation of the grouped mean (SEM) = 32 kcal.
[000488] The addition of xylanase, amylase, protease, and phytase, in combination with Enviva Pro or GalliPro Tect resulted in improvements in AMEn as a result of the control treatment, which were significantly greater compared to enzymes or DFMs alone. The increases in AMEn caused by the combination of xylanase, amylase, protease, phytase, and Enviva Pro (235 kcal / kg) or GalliPro Tect (215 kcal / kg) were greater than the addition of enzymes and the effects of DFM when applied separately ( 152 kcal / kg for Enviva Pro, or 120 kcal / kg for GalliPro Tect), compared to the negative control treatment. Example 8 Materials and methods
[000489] Fourteen hundred one-day-old male Cobb chicks were purchased from a commercial brooder. At the beginning of the study, fifty males were allocated to one of seven chicken houses for treatment by blocks. The study consisted of the following treatments (Table 1):
1 E. coli phytase. 2 Bacillus licheniformis amylase, Trichoderma reesei xylanase, Bacillus subtilis protease. 3 Enviva Pro ® is a combination of Bacillus subtilis strains Bs2084, LSSAO1 and 15AP4, supplied by Danisco A / S. 4 Axtra XAP ® supplied by Danisco A / S.
[000490] Bird weights per chicken coop were recorded at the beginning of the study, on the 21st and at the end (42nd). The chicken coop was the unit of measurement. The diets of broilers were given as bran (initial) or pellets (growing and finishing). Diets meet or exceed NRC standards (Table 2). The mixer was discarded to avoid cross contamination of the diets. All treatment rations were mixed using a Davis S-20 mixer and pelleted using a California Pellet Mill (cold pellet temperature 65 to 70 C). Samples were collected from each treatment diet at the beginning, middle and end of each batch and mixed together to confirm the enzymatic activities and the presence of Enviva Pro in the feed. Table 2. Composition of the experimental diet in example 8.

[000491] The birds received adequate feed for the treatment from day 0 to 42. The enzymes and Enviva Pro were supplied by Danisco in mixtures and levels suitable for all experimental treatments. All diets contained 500 FTU of E. coli phytase in the background. The chicken coops were arranged inside the facility to avoid direct contact in order to avoid contamination.
[000492] A change from the initial to the growth diet occurred on the 21st. The growth diet was replaced by the termination diet on the 35th. With each change in the ration, the feeders were removed from the chicken houses per block, weighed again, emptied and refilled with the proper treatment diet. On the final day of the study, the ration was weighed. The chicken houses were checked daily for mortality. When a bird was selected for slaughter or found dead, the date and weight of removal (kg) were recorded. A gross necropsy was performed on all birds killed or selected for slaughter to determine sex and the probable cause of death. Signs of necrotic enteritis were observed.
[000493] All chicken houses had approximately 10.2 cm (4 inches) of bed constructed with a fresh pine sawdust coating.
[000494] All birds were vaccinated by spraying before being placed in chicken houses with a commercial coccidiosis vaccine (Coccivac-B). On days 18, 19, and 20 all birds, except treatment 1, were administered with a culture broth of C. per-fringens. A field isolate of C. perfringens known to cause necrotic enteritis and which originates from an operation with commercial broilers was used as the stimulating organism. The fresh inoculum was used every day. The titration levels were approximately 1.0 X 108'9. Each chicken coop received the same amount of inoculum. The inoculum was administered by mixing it in the ration found at the base of the feed tube. Sample collection
[000495] On day 21, a total of 8 birds per treatment (1 to 2 birds per chicken coop) were euthanized and the total gastrointestinal tract from below the gizzard to the ileocecal junction was collected from each bird and sent from one day to the other on ice for the laboratory. The back samples were subsequently dissected in the laboratory to obtain a 20 cm portion of the jejunum surrounding Meckle's diverticulum; the remainder of the intestinal tract was discarded. The sections were rinsed with 0.1% peptone to remove the intestinal contents and opened longitudinally to expose the epithelial lining. The sections were chewed in 99 ml of 0.1% peptone at 7.0 beats / s for 60 s to release the bacterial cells associated with the mucosa. Bacteria were collected from the chewed solution by centrifugation at 12,000 x g for 10 minutes. The resulting bacterial pellet was resuspended in 10 ml of MRS broth + 10% glycerol, quickly frozen in liquid nitrogen, and stored at -20 ° C until further analysis. DNA isolation
[000496] Genomic DNA was isolated from all samples by extraction with chloroform phenol and purified using the High Pure PCR Template purification kit from Roche Applied Science (Roche Diagnostics Corp., Indianapolis, IN, USA). The samples were randomly grouped in pairs at the DNA level after extraction, for a total of four samples per treatment. Pyro sequencing
[000497] Pyrosquencing of the FLX amplicon encoded by the bacterial tag was done as described by Dowd (Dowd et al. 2008; BMC Microbiol. 8, 125). An equivalent amount of DNA isolated from the intestinal mucosa of each bird was analyzed in pooled samples containing DNA from two birds. The V1-V3 region of the 16S rRNA gene was amplified in each sample using primers 28 F (5'-GAGTTTGATCNTGGCTCAG) and 519R (5'-GTNTTACNGCGG- CKGCTG). After sequencing, the raw data were screened and adapted based on quality. The strings were classified by the individual samples based on barcode strings. Barcode labels were removed and non-bacterial ribosomal sequences were removed. The composition of the bacterial community was determined using BlastN comparison to a quality controlled and manually cured database derived from NCBI. The relative abundance of each bacterial ID was determined for each sample. The data were compiled at each taxonomic level using the NCBI nomenclature. Statistical analysis
[000498] The averages of the performance data were separated using paired t tests. Significant differences were considered at P <0.05. The chicken coops were used as the experimental unit.
[000499] Gender-level identifications were used for the analysis of pyro-sequencing data. The relative abundance of each genus was calculated and used for the analysis. The results were analyzed using a categorical model analysis and then a Chi-square probability was calculated using JMP 8.0.2 (SAS insti-tute, Cary, NC, USA), where each sample representing a bird it was considered an experimental unit. Results:
[000500] Figure 19 shows the feed conversion ratio (FCR) of broilers in a necrotic enteritis stimulus model (grouped SEM: 0.015).
[000501] The combination of Enviva Pro with xylanase, amylase, protease + phytase reduced FCR (g of PC gain / g of feed intake) compared to treatment with stimulated control and the use of only Enviva Pro and phytase. The feed conversion ratio was reduced by the combination to the level of unstimulated control + phytase.
[000502] Figure 20 shows the relative abundance of Lactobacillus spp. at 21 d in the jejunum mucosa of broilers, ChSq <0.0001.
[000503] Figure 20 shows the relative abundance of Lactobacillus spp. compared to other species in the jejunum mucosa of broilers in 21 days in a necrotic enteritis stimulation model. The proportion of Lactobacilli was reduced in the stimulated control compared to the non-stimulated control. The combination of Enviva Pro, xylanase, amylase, protease + phytase increases the proportion of Lactobacilli more than Enviva Pro and phytase alone and stimulated control.
[000504] Lactobacilli are widely used as probiotics for use in humans and animals (Patterson and Burkeholder 2003; Poult Sci 82 (4) 627-31) and have been documented to improve the health of the gastrointestinal tract to a level that could be comparable to antibiotic growth promoters (Awad et al. 2009 Poult Sci 88 (1) 49-56). Thus, by increasing the proportion of Lactobacilli in the microbiota of the gastrointestinal tract, the combination of Enviva Pro, xylanase, amylase, protease + phytase can improve the health of the gastrointestinal tract and positively affect feed efficiency.
[000505] All publications mentioned in the specification above are incorporated herein by reference. Various modifications and variations of the described methods and systems of the invention will become evident to those skilled in the art, without departing from the spirit and scope of the invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention, as claimed, should not be unduly limited to those specific embodiments. In fact, several modifications of the described embodiments of the invention, which are obvious to those skilled in biochemistry and biotechnology or related fields, are intended to be within the scope of the following claims.

权利要求:
Claims (19)
[0001]
1. Feed additive composition, characterized by the fact that it comprises a direct-fed micro-organism (DFM) in combination with a subtilis, a xylanase, a-amylase and a 6-phytase, in which the direct-feed microorganism comprises a bacteria from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens and their combinations, where 6-phytase is present in a dosage comprised between 200FTU / g of feed additive composition and 10,000 FTU / g of composition of feed additive, in which a-amylase is present in a dosage between 50 AU g of feed additive composition and 20,000 AU / g of feed additive composition, where xylanase is present in a dosage between 500 XU / g of feed additive composition and 40,000 XU / g of feed additive composition, where the subtilis is present in a dosage between 1,000 PU / g of feed additive composition and 60,000 PU / g of feed additive composition , is on that DFM is present in a dosage between 3.75x107 CFU / g of feed additive composition and 1x1011 CFU / g of feed additive composition.
[0002]
2. Feed additive composition according to claim 1, characterized by the fact that the feed microorganism is a viable bacterium.
[0003]
3. Feed additive composition according to claim 1 or 2, characterized by the fact that the direct feed microorganism is one or more of the following strains: Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B-50634).
[0004]
Feed additive composition according to any one of claims 1 to 3, characterized by the fact that the direct feed microorganism is in the form of an endospore.
[0005]
Feed additive composition according to any one of claims 1 to 4, characterized by the fact that xylanase is an endo-1,4-β-d-xylanase or a 1,4 β-xilosidase, preferably an endo -1,4-β-d-xylanase.
[0006]
Feed additive composition according to any one of claims 1 to 5, characterized by the fact that the xylanase is from Bacillus, Trichoderma, Thermomyces, Aspergillus, Penicillium or Humicola.
[0007]
Feed additive composition according to any one of claims 1 to 6, characterized in that the 6-phytase is an E. coli phytase or a Buttiauxella phytase or a Hafnia phytase or a Citrobacter phytase or a Aspergillus phytase or Penicillium phytase or Trichoderma phytase or Hansen ula phytase.
[0008]
Feed additive composition according to any one of claims 1 to 7, characterized by the fact that α-amylase is from Bacillus licheniformis, B. amyloliquefaciens, Trichoderma spp. or Aspergillus spp.
[0009]
9. Method of preparing a feed additive composition, characterized by the fact that it comprises the mixture of a direct-fed micro-organism with a subtilisin, a xylanase, a-amylase and a 6-phytase, in which the feed micro-organism Direct comprises a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens and their combinations.
[0010]
10. Method of preparing a feed additive composition, according to claim 9, characterized by the fact that it also comprises the conditioning of the feed additive composition.
[0011]
11. Feed, characterized by the fact that it comprises a feed additive composition as defined in any one of claims 1 to 8.
[0012]
12. Feed according to claim 11, characterized by the fact that 6-phytase is present in a dosage between 400 FSU / kg of feed and 1,000 FTU / kg of feed.
[0013]
13. Feed according to claim 11 or 12, characterized by the fact that a-amylase is present in a dosage between 100 AU / kg of feed and 2,000 AU / kg of feed.
[0014]
14. Feed according to any of claims 11 to 13, characterized by the fact that xylanase is present in a dosage between 1,000 XU / kg of feed and 4,000 XU / kg of feed.
[0015]
15. Feed according to any one of claims 11 to 14, characterized by the fact that the protease is present in a dosage between 2,000 PU / kg of feed and 6,000 PU / kg of feed.
[0016]
16. Feed according to any of claims 11 to 15, characterized by the fact that DFM is present in a dosage between 7.5x104 CFU / kg of feed and 1x107 CFU / kg of feed.
[0017]
17. Method of preparing a feed, characterized by the fact that it comprises mixing a feed component with a feed additive composition as defined in any one of claims 1 to 8.
[0018]
18. Premix, characterized by the fact that it comprises a feed additive composition comprising a direct feed microorganism in combination with a subtilisin, a xylanase, a-amylase and a 6-phytase, where the direct feed microorganism comprises a bacterium of one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens and their combinations.
[0019]
19. Premix, characterized by the fact that it comprises a feed additive composition as defined in any one of claims 1 to 8 in combination with a mineral and / or a vitamin.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10695384B2|2020-06-30|Feed additive composition

---

US11172693B2|2021-11-16|Feed additive composition

---

US20200276279A1|2020-09-03|Feed additive composition

---

US11235035B2|2022-02-01|Feed additive composition

---

JP2019500054A|2019-01-10|Composition for feed addition

---

BR112013020855B1|2021-11-03|FEED ADDITIVE COMPOSITION, KIT, METHOD TO PREPARE SUCH COMPOSITION, FEED, METHOD TO PREPARE A FEED, AND PREMIX

---

BR112015002191B1|2021-10-13|COMPOSITION OF ANIMAL FOOD ADDITIVE, KIT, ANIMAL FOOD AND PRE-MIXTURES

同族专利:

---

公开号 | 公开日

---

AU2012216898A1|2013-07-18|

---

PL2675286T3|2017-08-31|

---

DK2675286T3|2017-04-24|

---

US10695384B2|2020-06-30|

---

TW201234977A|2012-09-01|

---

WO2012110778A3|2012-10-26|

---

US20140234279A1|2014-08-21|

---

CN103533843A|2014-01-22|

---

BR112013020684A2|2016-10-25|

---

AR084893A1|2013-07-10|

---

EP2675286B1|2017-01-11|

---

CA2825618A1|2012-08-23|

---

ES2621137T3|2017-07-03|

---

AU2016201761B2|2017-08-10|

---

WO2012110778A2|2012-08-23|

---

JP2014507946A|2014-04-03|

---

US20190076488A1|2019-03-14|

---

EP2675286A2|2013-12-25|

---

GB201102857D0|2011-04-06|

---

AU2016201761A1|2016-04-07|

---

CA2825618C|2019-03-12|

---

ZA201305269B|2014-09-25|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB1011513A|1963-01-16|1965-12-01|Wayne Kerr Lab Ltd|Improvements in or relating to amplitude modulation measuring apparatus|

---

DK135983D0|1983-03-25|1983-03-25|Novo Industri As|THE AMYLASEENZYM SYMBOL PRODUCT AND PROCEDURE FOR ITS MANUFACTURING AND USING|

---

US4683202B1|1985-03-28|1990-11-27|Cetus Corp|

---

DK6488D0|1988-01-07|1988-01-07|Novo Industri As|ENZYMES|

---

AT129523T|1988-01-07|1995-11-15|Novo Nordisk As|SPECIFIC PROTEASE.|

---

US6287841B1|1988-02-11|2001-09-11|Genencor International, Inc.|High alkaline serine protease|

---

DK474589D0|1989-09-27|1989-09-27|Novo Nordisk As|PROCEDURE FOR THE PREPARATION OF BAKERY PRODUCTS|

---

EP0553280B2|1990-10-05|2010-08-11|Genencor International, Inc.|Methods for treating cotton-containing fabrics with cellulase|

---

DK13491D0|1991-01-25|1991-01-25|Novo Nordisk As|APPLICATION OF AN ENZYMOUS GRANULATE AND PROCEDURE FOR PREPARING A TABLET FORM|

---

WO1992019729A1|1991-05-01|1992-11-12|Novo Nordisk A/S|Stabilized enzymes and detergent compositions|

---

DK52393D0|1993-05-05|1993-05-05|Novo Nordisk As|

---

US5861271A|1993-12-17|1999-01-19|Fowler; Timothy|Cellulase enzymes and systems for their expressions|

---

AU7489896A|1995-11-02|1997-05-22|Novo Nordisk A/S|Feed enzyme preparations|

---

DE19619219A1|1996-05-13|1997-12-04|Hoechst Ag|Enzyme pre-granules for animal feed granules|

---

CA2270593C|1996-11-04|2005-06-07|Novo Nordisk A/S|Subtilase variants and compositions|

---

TW409035B|1997-06-04|2000-10-21|Gist Brocades Bv|Starch-based enzyme granulates|

---

CO5070700A1|1998-06-05|2001-08-28|Basf Ag|NOVELTY GENES OF POLYMERASE|

---

US6436451B1|1999-03-26|2002-08-20|Eggland's Best, Inc.|Method of reducing cholesterol in chicken eggs|

---

CN1622761A|2002-01-25|2005-06-01|Dsmip资产公司|Thermostable enzyme compositions|

---

WO2004085638A1|2003-03-25|2004-10-07|Republic Of National Fisheries Research And Development Institute|Phytase produced from citrobacter braakii|

---

US7618640B2|2004-05-14|2009-11-17|Agtech Products, Inc.|Method and composition for reducing E. coli disease and enhancing performance|

---

ITMI20041255A1|2004-06-22|2004-09-22|Univ Degli Studi Milano|MICROPARTICLE SYSTEMS FOR ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES|

---

EP1797178B1|2004-10-04|2012-09-12|DuPont Nutrition Biosciences ApS|Citrobacter freundii phytase and homologues|

---

AR050895A1|2004-10-04|2006-11-29|Novozymes As|POLYPEPTIDES THAT HAVE FITASA ACTIVITY AND POLYUCLEOTIDES THAT CODE THEM|

---

GB0422052D0|2004-10-04|2004-11-03|Dansico As|Enzymes|

---

AU2005291727B2|2004-10-04|2012-02-02|Novozymes A/S|Polypeptides having phytase activity and polynucleotides encoding same|

---

GB0423139D0|2004-10-18|2004-11-17|Danisco|Enzymes|

---

DE12159258T1|2005-10-12|2014-02-20|Danisco Us Inc.|Stable, durable granules with active ingredients|

---

US7754469B2|2005-11-30|2010-07-13|Agtech Products, Inc|Microorganisms and methods for treating poultry|

---

ES2531434T3|2006-04-04|2015-03-16|Novozymes A/S|Phytase variants|

---

US8309076B2|2006-08-04|2012-11-13|Bioneer Corporation|Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation|

---

EP2109356A2|2007-01-30|2009-10-21|Novozymes A/S|Polypeptides having phytase activty and polynucleotides encoding same|

---

CN101688192A|2007-02-07|2010-03-31|丹尼斯科美国公司|Carry out the starch hydrolysis with phytase and α-Dian Fenmei|

---

WO2008116878A1|2007-03-26|2008-10-02|Novozymes A/S|Hafnia phytase|

---

US20090100040A1|2007-04-03|2009-04-16|Scott Sheppard|Lawful interception of broadband data traffic|

---

CN100581386C|2007-06-19|2010-01-20|张观清|Core feed and complete feed used for producing health eggs without pollution|

---

CN101181016B|2007-12-13|2012-09-05|济南和美华饲料有限公司|Hen feedstuff for improving egg-laying performance|

---

US8021654B2|2008-03-14|2011-09-20|Danisco A/S|Methods of treating pigs with Bacillus strains|

---

WO2009129489A2|2008-04-18|2009-10-22|Danisco Us Inc., Genencor Division|Buttiauxella sp. phytase variants|

---

US7932495B2|2008-09-02|2011-04-26|ICT Integrated Circuit Testing Gesellschaft für Halbleiterprüftechnik mbH|Fast wafer inspection system|

---

PL2553090T3|2010-03-26|2019-08-30|Novozymes A/S|Thermostable phytase variants|GB201011513D0|2010-07-08|2010-08-25|Danisco|Method|

---

US20140314910A1|2011-11-17|2014-10-23|Novozymes A/S|Use of acid stable proteases in animal feed, preferably to increase performance of cocc-vaccinated broiler chickens|

---

ES2736036T3|2012-01-05|2019-12-23|Dupont Nutrition Biosci Aps|Feeding procedure|

---

GB201213801D0|2012-08-03|2012-09-12|Dupont Nutrition Biosci Aps|Feed additive composition|

---

EP2879511A1|2012-08-03|2015-06-10|Dupont Nutrition Biosciences ApS|Feed additive composition|

---

WO2014100612A1|2012-12-21|2014-06-26|Novozymes, Inc.|Methods for producing heterologous polypeptides in mutants of trichoderma|

---

US11179427B2|2013-01-21|2021-11-23|Eth Zurich|Baby food composition comprising viable propionic acid-producing bacteria|

---

US10006073B2|2013-05-24|2018-06-26|Chr, Hansen A/S|Use of Bacillus composition for increasing the amount of available sugars in animal feed|

---

US9888708B2|2013-10-15|2018-02-13|Purina Animal Nutrition Llc|Systems and methods for producing fermented milk replacer and methods of feeding same to animals|

---

US10463701B2|2013-12-31|2019-11-05|DuPont Nutrition BioScience ApS|Blends of Bacillus strains and enzymes|

---

WO2015128366A2|2014-02-25|2015-09-03|Dsm Ip Assets B.V.|A method for improving maize digestibility in bovine animals|

---

KR101735574B1|2014-05-13|2017-05-24|정명준|A Composition for poultry comprising fermented broth of Lactic acid bacteria and method for manufacturing the same|

---

CN104232507A|2014-07-22|2014-12-24|桐乡市五丰饲料有限公司|Composite micro-ecological preparation and application thereof in feed|

---

US20170246222A1|2014-10-08|2017-08-31|Novozymes A/S|Bacillus Strains with Fast Germination and Antimicrobial Activity against Clostridium|

---

EP3247788A1|2015-01-23|2017-11-29|Novozymes A/S|Bacillus strains improving health and performance of production animals|

---

CN104774819A|2015-02-24|2015-07-15|诺维信公司|Xylanase particles|

---

CA2981310A1|2015-04-10|2016-10-13|Syngenta Participations Ag|Animal feed compositions and methods of use|

---

EP3294308A4|2015-05-14|2019-03-06|University of Puerto Rico|Methods for restoring microbiota of newborns|

---

EP3344063A1|2015-09-01|2018-07-11|DuPont Nutrition Biosciences ApS|Methods of increasing fat soluble vitamin uptake in feed|

---

CN108366582A|2015-11-09|2018-08-03|杜邦营养生物科学有限公司|Feed addictive composition|

---

US11123410B2|2016-02-18|2021-09-21|Amanzo Enzyme Inc.|Intestinal flora improvement agent|

---

WO2017142080A1|2016-02-18|2017-08-24|天野エンザイム株式会社|Intestinal flora improvement agent|

---

KR101905322B1|2016-05-11|2018-10-08|경희대학교 산학협력단|Composition for immunity enhancement comprising a lactic acid bacterium|

---

KR101898138B1|2016-05-12|2018-09-12|주식회사 이뮤너스|Aquaculture functional feed additive comprising Lactococcus lactis BFE920 inducing regulatory T Cell|

---

EP3476226A4|2016-06-24|2019-12-04|Yessinergy Holding s/a|Immunomodulating and growth-promoting composition controlling the population of undesirable bacteria in the intestinal microbiota, and use thereof|

---

EP3825399A1|2016-06-30|2021-05-26|Danisco US Inc.|Aspartic proteases|

---

CN106360030A|2016-08-25|2017-02-01|广西河池市明达特种养殖专业合作社|Disease resistant feed for guinea pigs and production method of same|

---

CA3046872A1|2016-12-16|2018-06-21|Dupont Nutrition Biosciences Aps|Bacillus-based components for inhibiting or delaying the growth of enterococcus spp. in animals|

---

BR112019012662A2|2016-12-21|2020-01-28|Dupont Nutrition Biosci Aps|methods for using thermostable serine proteases|

---

CN107022537A|2017-03-03|2017-08-08|陈燕芳|A kind of keratinase compound and preparation method and application|

---

WO2018165252A1|2017-03-07|2018-09-13|Bioresource International, Inc.|Feed additive formulation and methods of making and using the same|

---

MX2019010815A|2017-03-15|2020-02-20|Dupont Nutrition Biosci Aps|Trypsin-like serine proteases and uses thereof cross-reference to related application.|

---

CN110621778A|2017-03-15|2019-12-27|丹尼斯科美国公司|Trypsin-like serine protease and uses thereof|

---

DK3596211T3|2017-03-15|2021-09-06|Dupont Nutrition Biosci Aps|PROCEDURES FOR USING AN ARCHAEA SERINE PROTEASE|

---

CN106858147A|2017-04-21|2017-06-20|深圳市湖大恩亿家农业科技有限公司|A kind of draft selenium-enriched SOD antibiotic-free feed and preparation method thereof|

---

KR102177029B1|2018-01-05|2020-11-10|벨벳케어|Gel-inducible composition for pet medication aid and method of administration using the same|

---

CN112654703A|2018-07-06|2021-04-13|杜邦营养生物科学有限公司|Xylanase-containing feed additives for cereal-based animal feed|

---

CN109125357A|2018-10-24|2019-01-04|南京益恒寿生命科技有限公司|A kind of probiotics that treating intestinal irritable syndrome-caprophyl liquid complex liquid|

---

TW202033100A|2018-11-20|2020-09-16|丹麥商杜邦營養生物科學有限公司|Engineered robust high tm-phytase clade polypeptides and fragments thereof|

---

KR102035261B1|2019-04-22|2019-10-22|신경섭|A composition of feed additives|

---

AU2020310162A1|2019-07-09|2022-02-03|Dupont Nutrition Biosciences Aps|Fat coated particulate enzyme compositions|

---

WO2021041357A1|2019-08-30|2021-03-04|Bioresource International, Inc.|Feed additive formulation for fish and methods of making and using the same|

---

WO2021046073A1|2019-09-05|2021-03-11|Dupont Nutrition Biosciences Aps|Feed composition|

---

WO2021102238A1|2019-11-20|2021-05-27|Dupont Nutrition Biosciences Aps|Thermostable phytase variants|

---

KR102173806B1|2019-11-20|2020-11-03|건국대학교 글로컬산학협력단|Lactobacillus plantarum KU18 and microorganism inoculant for silage production comprising the same|

---

WO2021127360A1|2019-12-19|2021-06-24|Dupont Nutrition Biosciences Aps|Diet formulations|

---

WO2021158927A1|2020-02-07|2021-08-12|Dupont Nutrition Biosciences Aps|Feed compositions for animal health|

---

WO2021173974A1|2020-02-28|2021-09-02|Dupont Nutrition Biosciences Aps|Feed compositions|

法律状态:
2018-02-14| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-03-27| B15K| Others concerning applications: alteration of classification|Ipc: A61K 35/741 (2015.01), A23K 10/18 (2016.01), A23K |

---

2018-05-15| B15K| Others concerning applications: alteration of classification|Ipc: A23K 10/18 (2016.01), A23K 20/189 (2016.01), A23K |

---

2018-10-02| B07A| Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]|

---

2019-08-27| B06G| Technical and formal requirements: other requirements [chapter 6.7 patent gazette]|

---

2020-02-04| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]|

---

2020-06-02| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-11-10| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/01/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

GBGB1102857.8A|GB201102857D0|2011-02-18|2011-02-18|Feed additive composition|

---

GB1102857.8|2011-02-18|

---

PCT/GB2012/050124|WO2012110778A2|2011-02-18|2012-01-19|Feed additive composition|

---